var title_f29_33_30224="Diabetic macular edema";
var content_f29_33_30224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F88023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F88023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Diabetic macular edema: appearance on optical coherence tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 137px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Optical coherence tomography (OCT) of diabetic macular edema. There are numerous large cysts visible within the macula (arrows), and the retinal thickness is increased.",
"    <br/>",
"    (B) OCT of normal macula (for comparison) showing typical foveal contour.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30224=[""].join("\n");
var outline_f29_33_30224=null;
var title_f29_33_30225="Virtual Iraq Humvee scenario";
var content_f29_33_30225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F59083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F59083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Virtual Iraq Humvee scenario from two user perspectives",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Skip Rizzo.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30225=[""].join("\n");
var outline_f29_33_30225=null;
var title_f29_33_30226="Achieving hemostasis after cone";
var content_f29_33_30226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achieving hemostasis after cervical (uterine cervix) conization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A surgical hemostatic pack (Surgicel) is placed into the unsutured cone bed and then secured in place by tying across with lateral cervical sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30226=[""].join("\n");
var outline_f29_33_30226=null;
var title_f29_33_30227="Sexual maturity rating of pubic hair in girls";
var content_f29_33_30227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sexual maturity rating (Tanner staging) of pubic hair development in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stages of development in pubic hair in girls.",
"    <br>",
"     Stage 1: Prepubertal with no pubic hair.",
"     <br>",
"      Stage 2: Sparse, straight hair along the lateral vulva.",
"      <br>",
"       Stage 3: Hair is darker, coarser, and curlier, extending over the mid-pubis.",
"       <br>",
"        Stage 4: Hair is adult-like in appearance, but does not extend to the thighs.",
"        <br>",
"         Stage 5: Hair is adult in appearance, extending from thigh to thigh.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30227=[""].join("\n");
var outline_f29_33_30227=null;
var title_f29_33_30228="Tinea versicolor KOH";
var content_f29_33_30228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examination of scale with 10 percent potassium hydroxide reveals both hyphae and spores in the characteristic \"spaghetti and meatballs\" pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30228=[""].join("\n");
var outline_f29_33_30228=null;
var title_f29_33_30229="Convent AP and lat rt port";
var content_f29_33_30229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiation therapy fields for cervical cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 647px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conventional anteroposterior, AP (A), and lateral (B) radiation portals for cervical cancer defined by a superior field border at the L4-L5 disk space, a inferior border extending 3 to 4 cm below the lowest extent of disease or the bottom of the obturator foramen, and a lateral edge 1.5 to 2 cm lateral to the pelvic brim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30229=[""].join("\n");
var outline_f29_33_30229=null;
var title_f29_33_30230="Spinal cord infarction: Clinical presentation and diagnosis";
var content_f29_33_30230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spinal cord infarction: Clinical presentation and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Michael Mullen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Michael L McGarvey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30230/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/33/30230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord infarction is a rare but often devastating disorder caused by a wide array of pathologic states. Patients typically present with acute paraparesis or quadriparesis, depending on the level of the spinal cord involved. The diagnosis is generally made clinically, with neuroimaging to confirm the diagnosis and exclude other conditions.",
"   </p>",
"   <p>",
"    This topic discusses the clinical features and diagnosis of spinal cord infarction. The vascular anatomy of the spinal cord, and the etiologies, prognosis, treatment, and chronic complications of spinal cord infarction are discussed separately. Other causes of myelopathy are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40631?source=see_link\">",
"     \"Spinal cord infarction: Vascular anatomy and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23333?source=see_link\">",
"     \"Spinal cord infarction: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cerebral infarction, the onset of spinal cord infarction is typically abrupt [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a few cases, symptoms progress over several minutes or even a few hours. The neurologic presentation of spinal cord infarction is largely defined by the vascular territory involved. The severity of the impairments can vary widely, from paraplegia to minor weakness. The involved cord level can be anywhere along the cord's length, depending in part on the underlying etiology. Back pain often accompanies spinal cord ischemia, and has been reported in as many as 70 percent of patients, typically occurring at the level of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anterior spinal artery syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of a spinal cord infarction is anterior spinal artery (ASA) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,5,8\">",
"     1,5,8",
"    </a>",
"    ]. Consistent with its functional neuroanatomy, an ASA infarct typically presents as loss of motor function and",
"    <span class=\"nowrap\">",
"     pain/temperature",
"    </span>",
"    sensation, with relative sparing of proprioception and vibratory sense below the level of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/9\">",
"     9",
"    </a>",
"    ]. The acute stages are characterized by flaccidity and loss of deep tendon reflexes; spasticity and hyperreflexia develop over ensuing days and weeks. Autonomic dysfunction may be present and can manifest as hypotension (either orthostatic or frank hypotension), sexual dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bowel and bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. In the acute evaluation of patients, it is important to recognize that hypotension may be both a cause as well as a manifestation of spinal cord ischemia. If the lesion is in the rostral cervical cord, respiration is compromised.",
"   </p>",
"   <p>",
"    While bilateral presentations are more common, unilateral ASA deficits are frequently reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,3-5,12\">",
"     1,3-5,12",
"    </a>",
"    ]. This occurs either because of occlusion of a unilateral sulcal artery, or because incomplete collateralization with the PSA maintains perfusion on one side of the cord. Very rostral ASA infarctions produce sensory loss in all modalities because of involvement of the medial lemniscus in the medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Posterior spinal artery syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior spinal artery (PSA) infarction produces loss of proprioception and vibratory sense below the level of the injury and total anesthesia at the level of the injury. Weakness has been described, but is typically mild and transient. Unilateral involvement is more common, but bilateral presentations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical presentations of spinal cord infarction that do not fit a well defined vascular distribution include Brown-Sequard syndrome, full transverse lesions similar to that found in cord transection, and central cord syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .) Additionally, we have observed cases of lower extremity weakness (unilateral and bilateral) without sensory loss. The etiology for this is unknown but likely relates to incomplete collateralization from the complex network of anastomosis that make up the spinal vascular supply. Among case series, these atypical, seemingly nonvascular syndromes comprise one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient symptoms lasting a few minutes to several hours, so-called spinal transient ischemic attacks (TIAs), have also been described in a variety of clinical settings, but these are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,4,13\">",
"     1,4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous infarction of the spinal cord has been described, usually in association with spinal vascular malformations. These infarcts may be either hemorrhagic or non-hemorrhagic. In non-hemorrhagic venous infarcts, venous hypertension decreases the arterial-venous pressure gradient leading to decreased perfusion. Non-hemorrhagic venous infarction typically present with a gradual onset of progressive neurologic decline, whereas hemorrhage is associated with the sudden onset of pain and flaccid paraparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H17#H17\">",
"     \"Disorders affecting the spinal cord\", section on 'Vascular malformations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are many potential causes of myelopathy, only a few present in an abrupt presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compressive myelopathy from neoplasm, epidural or subdural hematoma, or abscess is the most important category of diagnosis to exclude, as these often require urgent surgical decompression. While these lesions typically develop over time, the clinical presentation can be fairly abrupt and mimic spinal cord infarction. This diagnostic consideration mandates urgent neuroimaging in all patients presenting with spinal cord infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H26#H26\">",
"       \"Disorders affecting the spinal cord\", section on 'Neoplasms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"       \"Epidural abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transverse myelitis is more typically associated with an evolution of myelopathic symptoms over hours and days, but these can develop in as short a period as 10 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. A history of recent vaccination or viral illness may suggest this diagnosis, but these are often absent. Symptoms isolated to the anterior spinal artery territory suggest infarction over inflammation, but this is not definitive. Other diagnostic studies (lumbar puncture, brain imaging) may be required. Because individual clinical and diagnostic features are not sensitive or specific for either diagnosis, clinicians must consider the preponderance of the evidence when determining the more likely diagnosis. Clinical and diagnostic features that favor transverse myelitis over infarction include: progression of symptoms over at least a few hours, symptoms and MRI lesions that extend beyond a vascular territory, gadolinium enhancement, and cerebrospinal fluid findings of pleocytosis or elevated IgG levels [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H3#H3\">",
"       \"Disorders affecting the spinal cord\", section on 'Transverse myelitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute polyneuropathy (eg, Guillain-Barr&eacute; Syndrome (GBS)) can be confused with acute myelopathy because both are associated with flaccidity and loss of reflexes in the acute stage (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/17\">",
"       17",
"      </a>",
"      ]. Contributing to potential diagnostic confusion, is that back pain is a common feature in both GBS and acute spinal cord infarction. A history of ascending symptoms over time suggests GBS, while a sensory level and impaired bladder function suggest spinal cord infarction. In some cases, differentiating these diagnoses requires diagnostic tests (magnetic resonance imaging, electromyography) and the passage of time to allow upper motor neuron signs to emerge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the postoperative setting, the differential diagnosis of paraplegia includes an epidural hematoma, especially if the patient has had either a lumbar drain or epidural anesthesia. Although epidural hematoma usually has a more subacute presentation with evolution over time, this presentation may be obscured in the perioperative period [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with acute dissection or rupture of the descending aorta, paraplegia may result from impaired perfusion of the brain and lower extremities, as well as from spinal ischemia. It is also possible for all three of these phenomena to occur simultaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spinal MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is required in the diagnosis of spinal cord infarction. Perhaps its most important role is to rule out the alternative diagnosis of compressive myelopathy. MRI can also provide confirmatory evidence of spinal cord infarction and may provide information as to the underlying etiology. In most cases, this test should be performed urgently, although it may be deferred if the patient requires urgent aortic surgery or another life-saving intervention.",
"   </p>",
"   <p>",
"    MRI changes associated with spinal cord ischemia include hyperintensities on T2 weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72280 \" href=\"UTD.htm?26/46/27360\">",
"     image 1",
"    </a>",
"    ). The sensitivity of standard MRI is limited, particularly in the first several hours. The percentage of patients with T2 changes on MRI scan in published reports ranges from 45 to 73 percent depending in part on the scan's timing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,4,5,10,19,20\">",
"     1,4,5,10,19,20",
"    </a>",
"    ]. If clinical suspicion is high and the initial MRI is normal, follow-up imaging should be obtained. However, a significant minority of patients (14 percent in one series) will also have normal follow-up MRI scans [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]. A finding of restricted diffusion on diffusion weighted images (DWI-MRI) appears to be significantly more sensitive than standard T2 images, but the limited number of case reports preclude a numerical estimate of its sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A finding of T2 signal abnormality, even with restricted diffusion, is not specific for ischemia and can be seen in transverse myelitis and other intrinsic cord pathologies. When these findings are restricted to a vascular territory, they are more specific, but not perfectly so. A finding of vertebral body infarction adjacent to a cord signal abnormality on MRI is a specific indicator of ischemia and a useful confirmatory sign if present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this is found in only 4 to 35 percent of patients, and its absence does not exclude spinal cord infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/1,5,7\">",
"     1,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI may also help define the underlying etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervertebral disc disease at the level of infarction may suggest possible fibrocartilaginous embolism.",
"     </li>",
"     <li>",
"      Spondylotic disease may suggest a possible bony compression mechanism, particularly if the onset of symptoms is associated with activity involving twisting or torquing of the spine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spinal cord vascular malformations also have distinct patterns of abnormalities that may be seen on MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H17#H17\">",
"       \"Disorders affecting the spinal cord\", section on 'Vascular malformations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one case series, vertebral body infarction was highly associated with aortic disease pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further testing is not always necessary. As an example, in the setting of paraplegia after aortic surgery, a patient with typical spine MRI findings will likely not require further testing. However, depending on the clinical presentation, other tests should be ordered to further exclude alternative diagnoses (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    above) and to identify an underlying etiology (",
"    <a class=\"graphic graphic_table graphicRef57862 \" href=\"UTD.htm?5/36/5709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic dissection can be identified by multiplane transesophageal echocardiography (TEE), chest CT, and MRI. While an uncommon cause of spinal cord infarction, aortic dissection can lead to serious adverse sequelae if unrecognized. Therefore, this should be considered and specifically excluded in high-risk patients. Such patients will include those who present with prominent pain, abnormal distal pulses, known aortic aneurysm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an underlying collagen disorder (Marfan syndrome). A low threshold for this diagnosis should probably also include older adults with vascular risk factors in whom the underlying cause of spinal cord infarction is not immediately known. In patients with hemodynamic instability, this evaluation will take priority over spine imaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular imaging, either CT angiography or MR angiography, should be performed to exclude a vertebral artery dissection in a patient with a rostral cervical cord infarction.",
"     </li>",
"     <li>",
"      A gadolinium-enhanced MRI of the brain may be helpful to exclude multiple sclerosis if the clinical presentation is consistent with transverse myelitis.",
"     </li>",
"     <li>",
"      Echocardiography can be performed to look for a source of embolism.",
"     </li>",
"     <li>",
"      A lumbar puncture and cerebrospinal fluid (CSF) analysis should be performed in younger patients to look for signs of infection or inflammatory diseases. CSF testing should include cell count, protein, glucose, gram stain and culture,",
"      <span class=\"nowrap\">",
"       cytology/flow",
"      </span>",
"      cytometry, oligoclonal bands, as well as tests for syphilis, Lyme, herpes, varicella and cytomegalovirus. Serum tests for syphilis, Lyme, HIV, enterovirus, coxsackie a and b, adenovirus, and Epstein Barr virus may be of value. CSF analysis in spinal cord infarction is typically normal, but there can be pleocytosis (rarely more than 100 WBC) and an elevated protein (usually less than 119",
"      <span class=\"nowrap\">",
"       mg/dl)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/3,4,6,20\">",
"       3,4,6,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood tests to evaluate a possible hypercoagulable condition should be performed when the cause of spinal cord infarction is obscure, particularly in younger patients and those without vascular risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Urine or blood toxicology screen should exclude cocaine and other drugs of abuse.",
"      <br/>",
"      <br/>",
"      Rheumatologic tests are likely of low yield if there are no other suggestive clinical features, but these tests (sedimentation rate, antinuclear antibody, antineutrophil cytoplasmic antibodies, and",
"      <span class=\"nowrap\">",
"       SSA/B",
"      </span>",
"      antibodies) could be considered.",
"     </li>",
"     <li>",
"      A dedicated spinal angiogram is indicated when a vascular malformation is considered a possible etiology. In general, this is performed when the spine MRI has suspicious findings or when a patient presents with recurrent events. It may also be reasonable to consider this test in patients without recurrent events when the clinical suspicion for a vascular malformation is high. Despite the invasive nature of spinal angiography, observational studies suggest that in experienced hands, the complications are infrequent (1 to 2 percent) and do not involve significant morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30230/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H17#H17\">",
"       \"Disorders affecting the spinal cord\", section on 'Vascular malformations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord infarction is a rare condition caused by a wide array of pathologic conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with spinal cord infarction present with acute neurologic deficits attributable to the anterior spinal artery territory. However, one-third of patients may have less typical presentations including posterior spinal artery, central cord, and complete cord transection syndromes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute spinal cord infarction must be distinguished from lesions compressing the spinal cord. Transverse myelitis and acute demyelinating polyneuropathy are other important diagnostic considerations, depending on the clinical setting. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with spinal cord infarction should have a spine MRI to exclude a compressive myelopathy, as well as to provide further evidence supporting the diagnosis of infarction. Diffusion weighted images improve the sensitivity of MRI for acute ischemia; however, spine MRI findings have imperfect sensitivity and specificity for ischemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Spinal MRI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other tests can further exclude alternative diagnoses and identify the etiology. The choice of tests is tailored to the clinical situation. Clinicians should have a low threshold for excluding aortic dissection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/1\">",
"      Novy J, Carruzzo A, Maeder P, Bogousslavsky J. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol 2006; 63:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/2\">",
"      Cheng MY, Lyu RK, Chang YJ, et al. Spinal cord infarction in Chinese patients. Clinical features, risk factors, imaging and prognosis. Cerebrovasc Dis 2008; 26:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/3\">",
"      Sandson TA, Friedman JH. Spinal cord infarction. Report of 8 cases and review of the literature. Medicine (Baltimore) 1989; 68:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/4\">",
"      Cheshire WP, Santos CC, Massey EW, Howard JF Jr. Spinal cord infarction: etiology and outcome. Neurology 1996; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/5\">",
"      Nedeltchev K, Loher TJ, Stepper F, et al. Long-term outcome of acute spinal cord ischemia syndrome. Stroke 2004; 35:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/6\">",
"      Masson C, Pruvo JP, Meder JF, et al. Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 2004; 75:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/7\">",
"      Cheng MY, Lyu RK, Chang YJ, et al. Concomitant spinal cord and vertebral body infarction is highly associated with aortic pathology: a clinical and magnetic resonance imaging study. J Neurol 2009; 256:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/8\">",
"      Weidauer S, Nichtweiss M, Lanfermann H, Zanella FE. Spinal cord infarction: MR imaging and clinical features in 16 cases. Neuroradiology 2002; 44:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/9\">",
"      Foo D, Rossier AB. Anterior spinal artery syndrome and its natural history. Paraplegia 1983; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     Mohr JP, Benavente O, Barnett HJ. Spinal Cord Ischemia. In: Stroke Pathophysiology, Diagnosis, and Management, Barnett HJ, Mohr JP, Stein BM, Yatsu FM (Eds), Churchill Livingstone, Philadelphia 1998. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/11\">",
"      Cheung AT, Weiss SJ, McGarvey ML, et al. Interventions for reversing delayed-onset postoperative paraplegia after thoracic aortic reconstruction. Ann Thorac Surg 2002; 74:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/12\">",
"      STEEGMANN AT. Syndrome of the anterior spinal artery. Neurology 1952; 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/13\">",
"      Hussain MS, Shuaib A, Siddiqi ZA. Spinal cord transient ischemic attacks: a possible role for abciximab. Neurology 2005; 64:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/14\">",
"      Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/15\">",
"      Wilmshurst JM, Walker MC, Pohl KR. Rapid onset transverse myelitis in adolescence: implications for pathogenesis and prognosis. Arch Dis Child 1999; 80:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/16\">",
"      Nance JR, Golomb MR. Ischemic spinal cord infarction in children without vertebral fracture. Pediatr Neurol 2007; 36:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/17\">",
"      Hui AC, Wong KS, Fu M, Kay R. Ischaemic myelopathy presenting as Guillain-Barr&eacute; syndrome. Int J Clin Pract 2000; 54:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/18\">",
"      SreeHarsha CK, Rajasekaran S, Dhanasekararaja P. Spontaneous complete recovery of paraplegia caused by epidural hematoma complicating epidural anesthesia: a case report and review of literature. Spinal Cord 2006; 44:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/19\">",
"      Salvador de la Barrera S, Barca-Buyo A, Montoto-Marqu&eacute;s A, et al. Spinal cord infarction: prognosis and recovery in a series of 36 patients. Spinal Cord 2001; 39:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/20\">",
"      Robertson CE, Brown RD Jr, Wijdicks EF, Rabinstein AA. Recovery after spinal cord infarcts: long-term outcome in 115 patients. Neurology 2012; 78:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/21\">",
"      Thurnher MM, Bammer R. Diffusion-weighted MR imaging (DWI) in spinal cord ischemia. Neuroradiology 2006; 48:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/22\">",
"      Beslow LA, Ichord RN, Zimmerman RA, et al. Role of diffusion MRI in diagnosis of spinal cord infarction in children. Neuropediatrics 2008; 39:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/23\">",
"      K&uuml;ker W, Weller M, Klose U, et al. Diffusion-weighted MRI of spinal cord infarction--high resolution imaging and time course of diffusion abnormality. J Neurol 2004; 251:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/24\">",
"      Shinoyama M, Takahashi T, Shimizu H, et al. Spinal cord infarction demonstrated by diffusion-weighted magnetic resonance imaging. J Clin Neurosci 2005; 12:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/25\">",
"      Nogueira RG, Ferreira R, Grant PE, et al. Restricted diffusion in spinal cord infarction demonstrated by magnetic resonance line scan diffusion imaging. Stroke 2012; 43:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/26\">",
"      Faig J, Busse O, Salbeck R. Vertebral body infarction as a confirmatory sign of spinal cord ischemic stroke: report of three cases and review of the literature. Stroke 1998; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     Hurst RW. Spinal vascular disorders. In: Resonance Imaging of the Brain and Spine, 2nd, Atlas SW (Ed), Lippincott, Philadelphia 2006. p.1387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30230/abstract/28\">",
"      Chen J, Gailloud P. Safety of spinal angiography: complication rate analysis in 302 diagnostic angiograms. Neurology 2011; 77:1235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1117 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30230=[""].join("\n");
var outline_f29_33_30230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anterior spinal artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Posterior spinal artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spinal MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1117|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/46/27360\" title=\"diagnostic image 1\">",
"      MRI Spinal cord infarct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/36/5709\" title=\"table 1\">",
"      Causes of spinal cord infarct",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23333?source=related_link\">",
"      Spinal cord infarction: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40631?source=related_link\">",
"      Spinal cord infarction: Vascular anatomy and etiologies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_33_30231="Aldesleukin: Drug information";
var content_f29_33_30231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aldesleukin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/28/21957?source=see_link\">",
"    see \"Aldesleukin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39350?source=see_link\">",
"    see \"Aldesleukin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12806506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Biological Response Modulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider premedication with an antipyretic to reduce fever, an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last aldesleukin dose. Antibiotic prophylaxis is recommended to reduce the incidence of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal cell carcinoma:",
"     </b>",
"     I.V.: 600,000 units/kg every 8 hours for a maximum of 14 doses; repeat after 9 days for a total of 28 doses per course; retreat if tumor shrinkage observed (and if no contraindications) at least 7 weeks after hospital discharge date",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unlabeled dosing: 720,000 units/kg every 8 hours for up to 12 doses; repeat with a second cycle 10-15 days later (Klapper, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Melanoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Single-agent use:",
"     </i>",
"     600,000 units/kg every 8 hours for a maximum of 14 doses; repeat after 9 days for a total of 28 doses per course; retreat if tumor shrinkage observed (and if no contraindications) at least 7 weeks after hospital discharge date",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unlabeled dosing: 720,000 units/kg every 8 hours for 12-15 doses; repeat with a second cycle ~14 days after the first dose of the initial cycle (Smith, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination biochemotherapy (unlabeled use):",
"     </i>",
"     9 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours for 4 days every 3 weeks for up to 4 cycles (Atkins, 2008)",
"     <b>",
"      or",
"     </b>",
"     9 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours days 5 to 8, 17 to 20, and 26 to 29 every 42 days for up to 5 cycles (Eton, 2002)",
"     <b>",
"      or",
"     </b>",
"     9 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours for 4 days every 3 weeks for 6 cycles (Legha, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9647544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39350?source=see_link\">",
"      see \"Aldesleukin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider premedication with an antipyretic to reduce fever, an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last aldesleukin dose. Antibiotic prophylaxis is recommended to reduce the incidence of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML (unlabeled use):",
"     </b>",
"     I.V.: 9 million units (9 x 10",
"     <sup>",
"      6",
"     </sup>",
"     units)/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours daily for 4 days; repeat 4 days later with 1.6 million units (1.6 x 10",
"     <sup>",
"      6",
"     </sup>",
"     units)/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours daily for 10 days  (Lange, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2620612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific recommendations by manufacturer. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9647545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Withhold or interrupt a dose for toxicity; do not reduce the dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Cardiovascular toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Atrial fibrillation, supraventricular tachycardia, or bradycardia that is persistent, recurrent, or requires treatment: Withhold dose; may resume when asymptomatic with full recovery to normal sinus rhythm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Systolic BP &lt;90 mm Hg (with increasing pressor requirements): Withhold dose; may resume treatment when systolic BP &ge;90 mm Hg and stable or pressor requirements improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Any ECG change consistent with MI, ischemia or myocarditis (with or without chest pain), or suspected cardiac ischemia: Withhold dose; may resume when asymptomatic, MI/myocarditis have been ruled out, suspicion of angina is low, or there is no evidence of ventricular hypokinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      CNS toxicity:",
"     </i>",
"     Mental status change, including moderate confusion or agitation: Withhold dose; may resume when resolved completely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Dermatologic toxicity:",
"     </i>",
"     Bullous dermatitis or marked worsening of pre-existing skin condition: Withhold dose; may treat with antihistamines or topical products (do not use topical steroids); may resume with resolution of all signs of bullous dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Gastrointestinal:",
"     </i>",
"     Stool guaiac repeatedly &gt;3-4+: Withhold dose; may resume with negative stool guaiac.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hepatotoxicity:",
"     </i>",
"     Signs of hepatic failure, encephalopathy, increasing ascites, liver pain, hypoglycemia: Withhold dose and discontinue treatment for balance of cycle; may initiate a new course if indicated only after at least 7 weeks past resolution of all signs of hepatic failure (including hospital discharge).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Infection:",
"     </i>",
"     Sepsis syndrome, clinically unstable: Withhold dose; may resume when sepsis syndrome has resolved, patient is clinically stable, and infection is under treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Renal toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serum creatinine &gt;4.5 mg/dL (or &ge;4 mg/dL with severe volume overload, acidosis or hyperkalemia): Withhold dose; may resume when &lt;4 mg/dL and fluid/electrolyte status is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persistent oliguria or urine output &lt;10 mL/hour for 16-24 hours with rising serum creatinine: Withhold dose; may resume when urine output &gt;10 mL/hour with serum creatinine decrease of &gt;1.5 mg/dL or normalization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Respiratory toxicity:",
"     </i>",
"     Oxygen saturation &lt;90%: Withhold dose; may resume when &gt;90%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Retreatment with aldesleukin is contraindicated with the following toxicities:",
"      </i>",
"     </b>",
"     Sustained ventricular tachycardia (&ge;5 beats), uncontrolled or unresponsive cardiac arrhythmias, chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proleukin&reg;: 22 x 10",
"     <sup>",
"      6",
"     </sup>",
"     units [18 million units/mL = 1.1 mg/mL when reconstituted]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as I.V. infusion over 15 minutes (do not administer with an inline filter). Allow solution to reach room temperature prior to administration. Flush before and after with D",
"     <sub>",
"      5",
"     </sub>",
"     W, particularly if maintenance I.V. line contains sodium chloride. May also be administered by SubQ injection (unlabeled route)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, amphotericin B, calcium gluconate, diphenhydramine, fat emulsion 20%, fluconazole, foscarnet, gentamicin, magnesium sulfate, metoclopramide, morphine, ondansetron, piperacillin, ranitidine, sulfamethoxazole and trimethoprim,  tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fluorouracil, ganciclovir, lorazepam, pentamidine, prochlorperazine edisylate, promethazine, sodium chloride",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, heparin sodium, potassium chloride.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic renal cell cancer, metastatic melanoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F131284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute myeloid leukemia (AML)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aldesleukin may be confused with oprelvekin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proleukin&reg; may be confused with oprelvekin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (71%; grade 4: 3%), peripheral edema (28%), tachycardia (23%), edema (15%), vasodilation (13%), supraventricular tachycardia (12%; grade 4: 1%), cardiovascular disorder (11%; includes blood pressure changes, HF and ECG changes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (52%), confusion (34%; grade 4: 1%), fever (29%; grade 4: 1%), malaise (27%), somnolence (22%), anxiety (12%), pain (12%), dizziness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (42%), pruritus (24%), exfoliative dermatitis (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis (12%; grade 4: 1%), hypomagnesemia (12%), hypocalcemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (67%; grade 4: 2%), vomiting (19% to 50%; grade 4: 1%), nausea (19% to 35%), stomatitis (22%), anorexia (20%), weight gain (16%), abdominal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (37%; grade 4: 1%), anemia (29%), leukopenia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (40%; grade 4: 2%), AST increased (23%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Oliguria (63%; grade 4: 6%), creatinine increased (33%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (43%; grade 4: 1%), lung disorder (24%; includes pulmonary congestion, rales, and rhonchi), cough (11%), respiratory disorder (11%; includes acute respiratory distress syndrome, infiltrates and pulmonary changes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (66% to 74%), infection (13%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (10%), cardiac arrest (grade 4: 1%), MI (grade 4: 1%), ventricular tachycardia (grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Coma (grade 4: 2%), stupor (grade 4: 1%), psychosis (grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulation disorder (grade 4: 1%; includes intravascular coagulopathy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Anuria (grade 4: 5%), acute renal failure (grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (10%), apnea (grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic interstitial nephritis, anaphylaxis, angioedema, asthma, atrial arrhythmia, AV block, blindness (transient or permanent), bowel infarction/necrosis/perforation, bradycardia, bullous pemphigoid, capillary leak syndrome, cardiomyopathy, cellulitis, cerebral edema, cerebral lesions, cerebral vasculitis, cholecystitis, colitis, crescentic IgA glomerulonephritis, Crohn&rsquo;s disease exacerbation, delirium, depression (severe; leading to suicide), diabetes mellitus, duodenal ulcer, encephalopathy, endocarditis, extrapyramidal syndrome, hemorrhage (including cerebral, gastrointestinal, retroperitoneal, subarachnoid, subdural), hepatic failure, hepatitis, hepatosplenomegaly, hypertension, hyperuricemia, hypothermia, hyperthyroidism, inflammatory arthritis, injection site necrosis, insomnia, intestinal obstruction, intestinal perforation, leukocytosis, malignant hyperthermia, meningitis, myocardial ischemia, myocarditis, myopathy, myositis, neuralgia, neuritis, neuropathy, neutropenia, NPN increased, oculobulbar myasthenia gravis, optic neuritis, organ perfusion decreased, pancreatitis, pericardial effusion, pericarditis, peripheral gangrene, phlebitis, pneumonia, pneumothorax, pulmonary edema, pulmonary embolus, respiratory acidosis, respiratory arrest, respiratory failure, rhabdomyolysis, scleroderma, seizure, Stevens-Johnson syndrome, stroke, syncope, thrombosis, thyroiditis, tracheoesophageal fistula, transient ischemic attack, tubular necrosis, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aldesleukin or any component of the formulation; patients with abnormal thallium stress or pulmonary function tests; patients who have had an organ allograft.",
"     <b>",
"      Retreatment is contraindicated",
"     </b>",
"     in patients who have experienced sustained ventricular tachycardia (&ge;5 beats), uncontrolled or unresponsive  cardiac arrhythmias, chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adverse effects: Are frequent and sometimes fatal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Capillary leak syndrome:",
"     <b>",
"      [U.S. Boxed Warning]: High-dose aldesleukin therapy is associated with capillary leak syndrome (CLS), characterized by vascular tone loss and extravasation of plasma proteins and fluid into extravascular space. CLS results in significant hypotension and reduced organ perfusion which may be severe and can result in death.",
"     </b>",
"     CLS onset is immediately after treatment initiation. Cardiac arrhythmia, angina, MI, respiratory insufficiency (requiring intubation), gastrointestinal bleeding or infarction, renal insufficiency, edema and mental status changes are also associated with CLS. Monitor fluid status and organ perfusion status carefully; consider fluids and/or pressor agents to maintain organ perfusion. Withhold treatment for signs of organ hypoperfusion, including altered mental status, reduced urine output, systolic BP &lt;90 mm Hg or cardiac arrhythmia. Once blood pressure is normalized, may consider diuretics for excessive weight gain/edema. Recovery from CLS generally begins soon after treatment cessation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Withhold treatment for patients developing moderate-to-severe lethargy or somnolence; continued treatment may result in coma.",
"     </b>",
"     Mental status changes (irritability, confusion, depression) can occur and may indicate bacteremia, sepsis, hypoperfusion, CNS malignancy, or CNS toxicity. May cause seizure; use with caution in patients with seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Impaired neutrophil function is associated with treatment; patients are at risk for disseminated infection (including sepsis and bacterial endocarditis), and central line-related gram-positive infections. Treat pre-existing bacterial infection appropriately prior to treatment initiation.",
"     </b>",
"     Monitor for signs of infection or sepsis during treatment. Antibiotic prophylaxis which has been associated with a reduced incidence of staphylococcal infections in aldesleukin studies includes the use of oxacillin, nafcillin, ciprofloxacin, or vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune/inflammatory disorders: Use with caution in patients with autoimmune disease or inflammatory disorders; exacerbation and/or new onset have been reported with aldesleukin and interferon alfa combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiopulmonary disease:",
"     <b>",
"      [U.S. Boxed Warning]: Treatment with aldesleukin should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress and formal pulmonary function testing. Extreme caution should be used in patients with a history of prior cardiac or pulmonary disease",
"     </b>",
"     and in patients who are fluid-restricted or where edema may be poorly tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS metastases: Patients should be evaluated and treated for CNS metastases and have a negative scan prior to treatment. New neurologic symptoms and lesions have been reported in patients with out pre-existing evidence of CNS metastases; symptoms generally improve upon discontinuation, however, cases with permanent damage have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic function: May impair hepatic function; concomitant hepatotoxic agents may increase the risk of hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function: Patients must have a serum creatinine &le;1.5 mg/dL prior to treatment. May impair renal function; concomitant nephrotoxic agents may increase the risk of renal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Supportive care for high-dose treatment: Standard prophylactic supportive care during high-dose aldesleukin treatment includes acetaminophen to relieve constitutional symptoms and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist to reduce the risk of GI ulceration and/or bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The incidence of dyspnea and severe urogenital toxicities is potentially increased in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transplant patients: Enhancement of cellular immune function may increase the risk of allograft rejection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate patient selection: Perform a thorough clinical evaluation prior to treatment initiation. Exclude patients with significant cardiac, pulmonary, renal, hepatic, or central nervous system impairment from treatment. Patients with a more favorable performance status prior to treatment initiation are more likely to respond to aldesleukin treatment, with a higher response rate and generally lower toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contrast media: An acute array of symptoms resembling aldesleukin adverse reactions (fever, chills, nausea, rash, pruritus, diarrhea, hypotension, edema, and oliguria) were observed within 1-4 hours after iodinated contrast media administration, usually when given within 4 weeks after aldesleukin treatment, although  has been reported several months after aldesleukin treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician in a facility with cardiopulmonary or intensive specialists and intensive care facilities available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contrast Media (Non-ionic): May enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May diminish the antineoplastic effect of Aldesleukin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F131247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal toxicity and embryocidal effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if benefits to the mother outweigh potential risk to the fetus. Contraception is recommended for fertile males or females using this medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5520981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Proleukin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22000000 unit (1): $1411.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Baseline and periodic: CBC with differential and platelets, blood chemistries including electrolytes, renal and hepatic function tests, and chest x-ray; pulmonary function tests and arterial blood gases (baseline), thallium stress test (prior to treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monitoring during therapy should include daily (hourly if hypotensive) vital signs (temperature, pulse, blood pressure, and respiration rate), weight and fluid intake and output; in a patient with a decreased blood pressure, especially systolic BP &lt;90 mm Hg, cardiac monitoring for rhythm should be conducted. If an abnormal complex or rhythm is seen, an ECG should be performed; vital signs in these hypotension patients should be taken hourly and central venous pressure (CVP) checked; monitor for change in mental status, and for signs of infection.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Celeuk (JP);",
"     </li>",
"     <li>",
"      Interleukina 2 (PY);",
"     </li>",
"     <li>",
"      Interleukina II (CN);",
"     </li>",
"     <li>",
"      Proleukin (AR, AT, BE, BR, CH, CO, CZ, DE, DK, EC, EG, ES, FI, FR, GB, GR, HK, HN, HU, IE, IL, IT, KP, NL, NZ, PE, PL, PT, RU, SG, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aldesleukin is a human recombinant interleukin-2 product which promotes proliferation, differentiation, and recruitment of T and B cells, natural killer (NK) cells, and thymocytes; causes cytolytic activity in a subset of lymphocytes and subsequent interactions between the immune system and malignant cells; can stimulate lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4-7 L; primarily in plasma and then in the lymphocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Renal (metabolized to amino acids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: Initial: 6-13 minutes; Terminal: 80-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Atkins MB, Hsu J, Lee S, et al, &ldquo;Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5748-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/19001327/pubmed\" id=\"19001327\" target=\"_blank\">",
"        19001327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atkins MB, Lotze MT, Dutcher JP, et al, &ldquo;High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(7):2105-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/10561265/pubmed\" id=\"10561265\" target=\"_blank\">",
"        10561265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergmann L, Heil G, Kolbe K, et al, &ldquo;Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 1995, 16(3-4):271-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/7719235/pubmed\" id=\"7719235\" target=\"_blank\">",
"        7719235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein ZP, Porter MM, Gould M, et al, &ldquo;Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 86(9):3287-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/7579429/pubmed\" id=\"7579429\" target=\"_blank\">",
"        7579429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(8):2045-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/11956264/pubmed\" id=\"11956264\" target=\"_blank\">",
"        11956264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klapper JA, Downey SG, Smith FO, et al, &ldquo;High-Dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Response and Survival in Patients Treated in the Surgery Branch at the National Cancer Institute Between 1986 and 2006,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(2):293-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/18457330/pubmed\" id=\"18457330\" target=\"_blank\">",
"        18457330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange BJ, Smith FO, Feusner J, et al, &ldquo;Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: a Report From the Children's Oncology Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1044-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/18000167/pubmed\" id=\"18000167\" target=\"_blank\">",
"        18000167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, Ring S, Eton O, et al, &ldquo;Development of a Biochemotherapy Regimen With Concurrent Administration of Cisplatin, Vinblastine, Dacarbazine, Interferon Alfa, and Interleukin-2 for Patients With Metastatic Melanoma,&rdquo;",
"      <i>",
"       J Clin Onco",
"      </i>",
"      l, 1998, 16(5):1752-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/9586888/pubmed\" id=\"9586888\" target=\"_blank\">",
"        9586888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDermott DF, Regan MM, Clark JI, et al, &ldquo;Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(1):133-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/15625368/pubmed\" id=\"15625368\" target=\"_blank\">",
"        15625368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Kidney Cancer,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Melanoma,&rdquo; Version 1.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith FO, Downey SG, Klapper JA, et al, &ldquo;Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction With Vaccines,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(17):5610-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/18765555/pubmed\" id=\"18765555\" target=\"_blank\">",
"        18765555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang JC, Sherry RM, Steinberg, SM, et al, &ldquo;Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(16): 3127-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/33/30231/abstract-text/12915604/pubmed\" id=\"12915604\" target=\"_blank\">",
"        12915604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9413 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30231=[""].join("\n");
var outline_f29_33_30231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708605\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131251\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131288\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131255\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9647544\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131256\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2620612\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9647545\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131230\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131215\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131233\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131293\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131231\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131284\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131296\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131286\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131236\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131219\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298698\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131224\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131247\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131226\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131262\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5520981\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422186\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131228\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038320\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131218\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131235\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9413|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/28/21957?source=related_link\">",
"      Aldesleukin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39350?source=related_link\">",
"      Aldesleukin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_33_30232="Diagnostic ultrasound in neuromuscular disease";
var content_f29_33_30232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic ultrasound in neuromuscular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30232/contributors\">",
"     Francis O Walker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30232/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30232/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/33/30232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28971308\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic studies for suspected neuromuscular diseases have commonly included blood tests, nerve conduction studies, electromyography, and biopsy. Imaging has been limited to intraoperative observations and occasional MRI and CT scans. However, high resolution ultrasound has opened up this field to clinicians, and modestly priced portable instruments are now routinely available that can provide qualitative and quantitative details about nerve and muscle disease.",
"   </p>",
"   <p>",
"    This topic will review the use of ultrasound for the evaluation of neuromuscular disease. Electrodiagnostic methods for neuromuscular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971315\">",
"    <span class=\"h1\">",
"     TECHNICAL AND HISTORICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since its first use in the 1950s for medical practice, ultrasound has evolved into a sophisticated imaging modality employed by specialists to diagnose a broad range of clinical disorders. Early instruments depended on single linear echo latencies to measure fetal head width or midline shift in adults with suspected intracranial mass lesions. Current technology, however, provides real-time two-dimensional images that can be reconstructed into three dimensions (3D) and their change over time (4D) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/1\">",
"     1",
"    </a>",
"    ]. With the advent of inexpensive, portable units of sufficiently high resolution, the use of ultrasound in the evaluation of muscle and nerve disease is becoming commonplace.",
"   </p>",
"   <p>",
"    The physics of ultrasound is briefly reviewed here as it is pertinent to the study of muscle and nerve and is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link\">",
"     \"Echocardiography essentials: Physics and instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=see_link\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fundamental technique of ultrasound involves the insonation of tissue and analysis of the echoes reflected back to the insonating transducer. Reflected ultrasound occurs at interfaces within or between tissues of different acoustic impedance, a measure directly proportional to the speed at which sound travels through them. Bone conducts sound much faster than soft tissue; soft tissue slightly faster than water, but much faster than air. As such, the brightest echoes in the body are seen between bone and soft tissue. The use of coupling gel between skin and transducer minimizes the reflection that would otherwise occur between skin and air.",
"   </p>",
"   <p>",
"    The frequency of insonated sound determines resolution and depth of penetration. Higher frequencies provide better resolution of superficial structures because of their shorter wavelengths, but lower frequencies provide better images of deep structures, albeit at somewhat lower resolution. This is the same principle that explains why the low pitched rumble of thunder is audible for miles, but the sharp, high pitched sounds are only heard with nearby lightening strikes. Intraluminal ultrasound probes offer one means of obtaining high resolution in certain types of deep structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to acoustic impedance, another property known as anisotropy is relevant to sonographic differentiation. Anisotropy is the tendency of tissues to reflect sound in a directionally dependent manner, as opposed to diffusely scattering the reflection. Different tissues exhibit variable degrees of anisotropy, and higher degrees of anisotropy result in differences in echogenicity when the ultrasound probe angle is changed. Using frequent, subtle adjustments in probe alignment, the skilled sonographer differentiates structures by observing the extent of this property in insonated tissues. As an example, tendons appear highly echogenic when the ultrasound probe is angled perpendicular to the tendon, but look almost anechoic when the probe is angled obliquely [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/2\">",
"     2",
"    </a>",
"    ]. Holding the probe perpendicular to the target minimizes the impact of anisotropy and is an approach often used to obtain standardized images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56630 \" href=\"UTD.htm?27/49/28434\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Almost any imaging probe can be used to study muscle, although small muscles, such as extensor digitorum brevis, are best evaluated using high-resolution transducers. Much of the literature on muscle ultrasound (often referred to as musculoskeletal ultrasound) deals with the study of structural disorders of muscle such as strains, tears, hernias, hematomas, tumors, and other mass lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In these conditions, the patient often can point to where the problem is. This report will primarily focus on uses of ultrasound in the study of neurologic disorders of muscle and nerve, where knowledge of localization is critical for identifying pathology and the distribution of neuromuscular involvement.",
"   </p>",
"   <p>",
"    Ultrasound offers advantages over computed tomography and magnetic resonance imaging in that it provides real-time and dynamic capabilities, superior edge-to-edge resolution, and lower cost. However, it only provides a keyhole aperture, and as such, optimal use of ultrasound involves sophisticated clinical input to determine specifically where to look for pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971322\">",
"    <span class=\"h1\">",
"     ULTRASOUND OF NORMAL MUSCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy muscle tissue has a distinctive appearance on ultrasound that readily distinguishes it from other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In the axial image, muscle consists of primarily echolucent (dark) areas interspersed with small bright curved echoes of seemingly random orientations. In the sagittal plane, however, these bright echoes are seen to be the fibrous tissue that surrounds muscle fibers and fascicles and which organizes into recognizable striations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68360 \" href=\"UTD.htm?22/42/23203\">",
"     image 2",
"    </a>",
"    ). In bipennate or multipennate muscles, a central aponeurosis can often be identified as an area of thickened fibrous tissue. If followed distally, this structure becomes the tendon. The angle of pennation is critical for determining force dynamics of muscle; because it is distorted in cadaveric specimens, studies involving this parameter should ascertain it from real-time imaging to make accurate determinations of in-vivo muscle function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971329\">",
"    <span class=\"h2\">",
"     Ultrasound of muscle motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;At rest, normal muscle is static with the exception of visible arterial pulsations. However, with slow contraction, the central portion of muscle can be seen to bulge with thinning of its more distal ends. In the area of bulging, thickening muscle fascicles can be seen to jostle for space in the increasingly pressurized environment (",
"    <a class=\"graphic graphic_movie graphicRef76097 \" href=\"UTD.htm?38/57/39839\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/6\">",
"     6",
"    </a>",
"    ]. In the sagittal view the angle of pennation can be seen to change as the muscle moves through its range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/7\">",
"     7",
"    </a>",
"    ]. The bulk of muscle thickening occurs with low levels of muscle contraction and effort, which explains why body builders can demonstrate their physique while retaining a relaxed expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound can also be used to investigate kinesiology. As an example, with isometric dorsiflexion of the foot, the interosseous membrane separating the tibialis anterior from the tibialis posterior bulges posteriorly; with isometric foot inversion, it bulges anteriorly, reflecting the different activation of these two muscles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81006 \" href=\"UTD.htm?14/46/15075\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971336\">",
"    <span class=\"h1\">",
"     ULTRASOUND OF DISEASED MUSCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is capable of providing useful real time feedback on the size of muscle and the presence of chronic pathologic changes in muscle. With special quantitative adaptations, the technique may provide additional information about more subtle or acute abnormalities.",
"   </p>",
"   <p>",
"    Primary nerve and muscle diseases are associated with atrophy, increased echodensity, and loss of intrinsic heterogeneity by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The highly organized nature of the myofibrillar structure of healthy muscle is conducive to sound transmission, whereas fat, inflammation, and fibrosis generate multiple microscopic reflectors of sound. As the muscle becomes more echogenic, it becomes difficult to distinguish muscle tissue from its supporting fibrous stroma, making the image more homogeneous. Another result of increased echogenicity is that tissues or structures deep to muscle tend to be less well visualized on ultrasound. Deep bone reflections and shadowing often are obscured as a result of the loss of penetrating sound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike needle electromyography of muscle, which shows characteristic differences between myopathic and neurogenic findings, ultrasound often does not show a distinct difference between myopathic and neurogenic conditions pathology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55106 \" href=\"UTD.htm?34/50/35623\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60063 \" href=\"UTD.htm?25/15/25841\">",
"     image 5",
"    </a>",
"    ). However, the distribution of affected muscles often is informative with respect to etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. Myopathies generally tend to affect proximal muscles and polyneuropathies tend to affect distal muscles. In addition, myopathies often have characteristic distributions, affecting certain muscles more than others. As an example, inclusion body myopathy has a predilection for flexor pollicis longus but spares its antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/9\">",
"     9",
"    </a>",
"    ]. Unilateral changes restricted to a single root or nerve distribution are highly suggestive of focal nerve lesions. In some disorders, such as Duchenne muscular dystrophy, muscle enlargement occurs, and ultrasound effectively identifies hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute severe denervation of muscle leads to increased water content and swelling that cause measurable changes in echogenicity with sophisticated imaging analysis software [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, to simple inspection, such changes are equivocal, unlike changes by electromyography, which can be striking.",
"   </p>",
"   <p>",
"    The utility of muscle ultrasound for the diagnosis of neuromuscular disorders is evolving, particularly in specialized ultrasound centers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/14\">",
"     14",
"    </a>",
"    ]. In a 2008 review of prospective case-control studies, the sensitivities of visual evaluation of muscle echo intensity for the detection of a neuromuscular disorder in children ranged from 67 to 81 percent, and corresponding specificities ranged from 84 to 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/15\">",
"     15",
"    </a>",
"    ]. Among studies using methods that quantified muscle echo intensity (eg, by computerized image analysis), the sensitivities were higher and ranged from 87 to 92 percent. Thus, quantitative techniques may yield further improvements in the diagnostic utility of ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium deposition within muscle, a finding frequently seen following trauma, is easily identified by ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66872 \" href=\"UTD.htm?42/25/43411\">",
"     image 6",
"    </a>",
"    ). Subcutaneous vascular calcifications are also readily apparent with this technique, and may be seen in some inflammatory myopathies. Metabolic disorders of muscle, if they are not associated with significant histopathologic changes, typically do not show much change on ultrasound. Similarly, injection of botulinum toxin does little to alter muscle architecture and causes no change in echotexture. However, a single botulinum toxin injection causes measurable loss of muscle thickness at six weeks. This finding suggests that ultrasound might be useful as a biomarker to measure the progression of neuromuscular disease. In addition, ultrasound might be useful to assess the efficacy of therapeutic agents that slow the progression of muscle loss, or reverse atrophy of muscle, should such agents be found effective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971343\">",
"    <span class=\"h2\">",
"     Dynamic changes in diseased muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most striking dynamic change in diseased muscle is probably the occurrence of fasciculations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/6\">",
"     6",
"    </a>",
"    ]. These result from spontaneously discharging motor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/18\">",
"     18",
"    </a>",
"    ]. Fasciculations cause contraction of the entire motor unit (the motor axon and all the muscle fibers it innervates). Clinically, a fasciculation appears as a focal twitch in a muscle, and most patients with fasciculations have multiple different motor units that discharge erratically. Many fasciculations, detected by either electromyography (EMG) or by ultrasound, are not clinically apparent, as clinical recognition depends on their proximity to the surface of the muscle, the depth below the skin, and the size of the motor unit involved. Ultrasound may be more sensitive than EMG at detecting fasciculations, probably because it samples a larger muscle region than needle EMG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/6,15,19\">",
"     6,15,19",
"    </a>",
"    ]. However, it may be difficult to detect fasciculations on ultrasound in patients who are unable to completely relax. Ultrasound allows specific aspects of fasciculations to be studied, such as twitch contraction time, contraction and relaxation durations, cross sectional area involved by the twitch, and recurrence and serial study, but these features are largely of research significance (",
"    <a class=\"graphic graphic_movie graphicRef60193 \" href=\"UTD.htm?37/9/38032\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of other aspects of altered dynamic function of muscle are amenable to study by ultrasound, such as changes in angles of pennation in disorders of muscle shortening, loss of contractile thickening in myopathy or neurogenic weakness, slowed or increased relaxation times in thyroid disease, or myotonia or cramp, but such studies have largely gone unperformed. Several reports indicate that high resolution ultrasound can image fibrillations in muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. While this finding needs further verification, it would have significant ramifications regarding the evolution of the field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971350\">",
"    <span class=\"h1\">",
"     ULTRASOUND OF NORMAL NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With currently available high-end instrumentation and high-resolution probes, major upper extremity nerves and their distal branches can be followed from the axilla into the digits in the average patient. In the lower extremity, nerves can be followed from the gluteal region to the feet, but given the large diameter of the legs and the thickness of the feet and sole, it is more difficult to resolve proximal portions of the nerve and terminal branches. Portions of the brachial plexus are readily visible by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/22\">",
"     22",
"    </a>",
"    ], but the lumbosacral plexus, because of its deep location, is not easily imaged in adults.",
"   </p>",
"   <p>",
"    Nerves have a distinct appearance on ultrasound, but there is some variation in relation to nerve thickness and surrounding structures. A typical nerve has a honeycomb appearance with a somewhat echogenic external perineurium punctuated by hypoechoic rounded fascicles (",
"    <a class=\"graphic graphic_movie graphicRef71933 \" href=\"UTD.htm?10/26/10656\">",
"     movie 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5,23,24\">",
"     5,23,24",
"    </a>",
"    ]. The number of apparent fascicles increases with the resolution of the ultrasound instrument. In contrast, nerve fascicles are not delineated on either CT or 3 Tesla MRI scans. At the wrist, when surrounded by hyperechoic tendons, the nerve appears relatively hypoechoic, and with lower resolution probes, the nerve has a speckled appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. The ulnar nerve at the elbow, perhaps because of its approximation to the bony medial epicondyle, may seem somewhat hypoechoic. In general, nerves are rounded, but their shape varies as they course through the extremity, sometimes assuming a triangular or oval shape in accordance with the tissues they pass through. The median nerve normally flattens in the wrist as it enters the carpal tunnel.",
"   </p>",
"   <p>",
"    The fascicular anatomy of nerve is somewhat complex. Major nerve branches are often separate but conjoined within the same nerve sheath for some distance. The peroneal and tibial branches of the sciatic nerve are most striking in this regard, but the motor and sensory branches of the radial nerve are separated into distinct fascicles well before the nerve branches in the forearm (",
"    <a class=\"graphic graphic_movie graphicRef58279 \" href=\"UTD.htm?36/12/37056\">",
"     movie 4",
"    </a>",
"    ). Branch points are most easily seen when the nerves split in the same horizontal plane as the direction of the nerve trunk. Deep or diving intramuscular branches are sometimes more difficult to image.",
"   </p>",
"   <p>",
"    The brachial plexus has distinct anatomy (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/22\">",
"     22",
"    </a>",
"    ]. The cervical nerve roots, although not visible within the spine, are visible shortly after exiting from the spinal foramina, and they can be seen descending in grouped bundles of fascicles to the subclavian artery. Although gross dissection reveals discrete trunks and cords, it is difficult to define their boundaries with ultrasound in the paraclavicular region where they are compacted together. The plexus can be difficult to image in the subclavicular region, but the nerves are more superficial and readily apparent in the axilla.",
"   </p>",
"   <p>",
"    In general, nerves are readily distinguished from tendons, in that they are not freely movable, have different anatomic paths, and show less anisotropy. They are readily distinguished from arteries and veins because they do not pulsate and do not compress. In rare cases where there is venous thrombosis, the unique fascicular structure of the nerve, as well as its course and branching, should be sufficient to differentiate it from other structures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distal portions of cranial nerves can also be imaged with ultrasound. The optic nerve is visible within the orbit, but heat generated by the ultrasound probe can acutely cause cataracts in animals. Therefore, optic nerve evaluations should be done with specialized and safety-checked equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/25\">",
"     25",
"    </a>",
"    ]. Branches of the facial nerve can occasionally be imaged as they course through the parotid gland, and both the spinal accessory and vagus nerves can be imaged in the cervical region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971357\">",
"    <span class=\"h2\">",
"     Normal nerve movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerves need to be able to move as extremities flex and extend, and as such are capable of movement in a",
"    <span class=\"nowrap\">",
"     proximal/distal",
"    </span>",
"    gradient. Ultrasound can demonstrate this type of movement, and also movement relative to nearby structures. For example, with fisting and extreme flexion of the wrist, the median nerve, which is normally situated on the palmar surface of the carpal tunnel, rotates 90 degrees and dives below the other flexor tendons, an observation only apparent with real-time ultrasound (",
"    <a class=\"graphic graphic_movie graphicRef74182 \" href=\"UTD.htm?36/7/36991\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53081 \" href=\"UTD.htm?27/11/27824\">",
"     movie 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In addition, the nerve can be seen to move proximally and distally with flexion and extension of the digits, although much less than the tendons move [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, the ulnar nerve in the ulnar groove and the sciatic nerve proximal to the popliteal fossa can be seen to move relative to nearby structures with flexion of the extremity, and subluxation of the ulnar nerve out of the ulnar groove is readily apparent with dynamic imaging (",
"    <a class=\"graphic graphic_movie graphicRef64956 \" href=\"UTD.htm?16/22/16751\">",
"     movie 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971364\">",
"    <span class=\"h1\">",
"     ULTRASOUND OF NERVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution ultrasound is particularly informative with respect to nerve compression syndromes, such as carpal tunnel syndrome, and focal enlargement of the nerve is a robust indicator of local pathology. The technique may be useful for the study of inflammatory and traumatic neuropathies, and can identify neoplastic changes in nerves as well. Further studies are needed to determine the specificity and sensitivity of the technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971372\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve swelling is a prominent finding in carpal tunnel syndrome (CTS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=see_link\">",
"     \"Etiology of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have shown that the median nerve is enlarged and often hypoechoic in CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/27-30\">",
"     27-30",
"    </a>",
"    ], a finding that confirms a fundamental observation of surgeons who had noted that the median nerve frequently appeared swollen in patients with this disorder. The ultrasound finding is somewhat counterintuitive in that it is tempting to assume that the nerve is physically smaller in areas where it is compressed, and that it should be hyperechoic due to either reduction of",
"    <span class=\"nowrap\">",
"     myelin/axonal",
"    </span>",
"    girth or inflammation. However, detailed studies confirm that overall the median nerve is increased in size in CTS, typically even in areas of compression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/31\">",
"     31",
"    </a>",
"    ]. Because of the distal-proximal sliding of the median nerve at the wrist, the precise site in the carpal tunnel of maximal enlargement of the nerve may vary somewhat from wrist to wrist.",
"   </p>",
"   <p>",
"    The underlying mechanism of nerve swelling with focal compression is hypothesized to be related to damming of axoplasmic flow and increased small vessel blood flow, findings that are consistent with the reduced nerve echogenicity seen on ultrasound. Studies in animals with experimental low-grade compression of nerves show similar swelling distal and proximal to the compressed area, and it seems likely that this is common to many nerve entrapments [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/32-37\">",
"     32-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional abnormalities that occur in CTS include flattening of the median nerve, and on occasion, diminished dimensions of the carpal tunnel itself [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/38\">",
"     38",
"    </a>",
"    ]. Other evidence has suggested that nerves are less mobile in CTS, and in our experience, the nerve is less likely to move relative to the tendons in the carpal tunnel in affected patients. It is unclear how robust this finding is or if it is secondary to enlargement of the nerve or whether it reflects intrinsic changes in the freedom of movement of the nerve. Further studies should be informative. Studies looking at proximal and distal movement of the median nerve in CTS have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/26,39\">",
"     26,39",
"    </a>",
"    ]. It is technically challenging to measure this type of movement as it is difficult to identify discrete landmarks in the nerve as it moves in the sagittal plane. Other findings, such as a bifid median nerve, or a persistent median artery, may be relevant with regard to choosing a surgical approach to the disorder (",
"    <a class=\"graphic graphic_movie graphicRef76718 \" href=\"UTD.htm?34/48/35599\">",
"     movie 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971379\">",
"    <span class=\"h2\">",
"     Other compressive neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of ultrasound studies on nerve compression have examined patients with carpal tunnel syndrome, other studies of compressed nerve, such as the ulnar nerve at the elbow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71846 \" href=\"UTD.htm?24/41/25236\">",
"     image 7",
"    </a>",
"    ), have shown that nerve swelling is common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. While the data are limited, the absence of conflicting findings suggests that focal nerve enlargement is a robust indicator of local pathology. Continued study of patients with focal neuropathies should be informative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971386\">",
"    <span class=\"h2\">",
"     Other forms of focal nerve pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of literature supports the usefulness of ultrasound in identifying other types of nerve lesions. Perhaps most instructive are case reports demonstrating the ability of ultrasound to identify transected or crushed nerves, findings that have unequivocal surgical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The sensitivity and specificity of ultrasound in such disorders is unknown, and will likely depend on the experience of the operator, the resolution of the instrument, and the degree of surrounding soft tissue changes associated with trauma. Other types of gross nerve lesions are readily identified by ultrasound, including neuromas (",
"    <a class=\"graphic graphic_movie graphicRef51601 \" href=\"UTD.htm?30/3/30774\">",
"     movie 9",
"    </a>",
"    ), ganglion cysts, neurofibromas, and other focal nerve tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20833577\">",
"    <span class=\"h2\">",
"     Polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest reports of ultrasound of nerve disease were in hypertrophic neuropathies, such as Charcot-Marie-Tooth disease, in which palpably enlarged nerves were confirmed to be of increased size with ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/52\">",
"     52",
"    </a>",
"    ]. In these cases, diffuse chronic nerve enlargement was expected based on the known pathology of the disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant enlargement of nerves in the brachial plexus and in the limbs is common with inflammatory neuropathies such as chronic inflammatory demyelinating neuropathy (CIDP) and multifocal motor neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a report that used ultrasound to measure the cross-sectional areas of median and ulnar nerves, the results from 100 adult and pediatric subjects who had various neuropathies were compared with those from 90 healthy control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/56\">",
"     56",
"    </a>",
"    ]. Nerve enlargement was found in the following proportions of subjects with neuropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with Charcot-Marie-Tooth 1A, all 11 (100 percent)",
"     </li>",
"     <li>",
"      For patients with CIDP, 31 of 36 (86 percent)",
"     </li>",
"     <li>",
"      For patients with Guillain-Barr&eacute; syndrome, 8 of 17 (47 percent)",
"     </li>",
"     <li>",
"      For patients with axonal neuropathy, 7 of 36 (19 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with CIDP, nerve enlargement increased with longer time from disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/56\">",
"     56",
"    </a>",
"    ]. In those with Guillain-Barr&eacute; syndrome, nerve enlargement was found as early as five days and as late as 15 years after onset of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further studies are needed to verify the sensitivity and specificity of ultrasound for the diagnosis of these neuropathies, and to delineate when nerve abnormalities are likely to be detected by ultrasound during the course of an evolving illness.",
"   </p>",
"   <p>",
"    Routine inspection of cases of axonal neuropathy has not shown obvious loss of nerve cross-sectional area. In theory, a reduction in nerve cross sectional area could be a manifestation of nerve loss in some disorders such as motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30232/abstract/57\">",
"     57",
"    </a>",
"    ]. Further ultrasound studies may be informative in such conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28971393\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy muscle tissue has a distinctive appearance on ultrasound that readily distinguishes it from other tissues. In the axial image, muscle consists of primarily echolucent (dark) areas interspersed with small linear or curvilinear bright echoes. In the sagittal plane, these bright echoes are seen to be the fibrous tissue that surrounds both muscle fibers and fascicles, and is organized into recognizable striations (See",
"      <a class=\"local\" href=\"#H28971322\">",
"       'Ultrasound of normal muscle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On ultrasound of muscle, both neurogenic and primary muscle diseases are associated with atrophy, increased echodensity, and loss of intrinsic heterogeneity. In some disorders, such as Duchenne muscular dystrophy, muscle enlargement occurs, and ultrasound effectively identifies hypertrophy. The most striking dynamic change in diseased muscle is probably the occurrence of fasciculations. (See",
"      <a class=\"local\" href=\"#H28971336\">",
"       'Ultrasound of diseased muscle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With high-end ultrasound instrumentation and high-resolution probes, major upper extremity nerves and their distal branches can be followed from the axilla into the digits in the average patient. In the lower extremity, nerves can be followed from the gluteal region to the feet, but given the large diameter of the legs and the thickness of the feet and sole, it is more difficult to resolve proximal portions of the nerve and terminal branches. Portions of the brachial plexus are readily visible by ultrasound, but the lumbosacral plexus, because of its deep location, is not easily imaged in adults. (See",
"      <a class=\"local\" href=\"#H28971350\">",
"       'Ultrasound of normal nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High resolution ultrasound is particularly informative with respect to nerve compression syndromes, such as carpal tunnel syndrome, and focal enlargement of the nerve appears to be a robust indicator of local pathology. Ultrasound may be useful for the study of inflammatory and traumatic neuropathies, and can identify neoplastic changes in nerves as well. (See",
"      <a class=\"local\" href=\"#H28971364\">",
"       'Ultrasound of nerve disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/1\">",
"      Tonni G, Centini G, Rosignoli L. Prenatal screening for fetal face and clefting in a prospective study on low-risk population: can 3- and 4-dimensional ultrasound enhance visualization and detection rate? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/2\">",
"      Crass JR, van de Vegte GL, Harkavy LA. Tendon echogenicity: ex vivo study. Radiology 1988; 167:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/3\">",
"      Campbell SE, Adler R, Sofka CM. Ultrasound of muscle abnormalities. Ultrasound Q 2005; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/4\">",
"      Lee JC, Healy J. Sonography of lower limb muscle injury. AJR Am J Roentgenol 2004; 182:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/5\">",
"      Walker FO. Neuromuscular ultrasound. Neurol Clin 2004; 22:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/6\">",
"      Walker FO, Donofrio PD, Harpold GJ, Ferrell WG. Sonographic imaging of muscle contraction and fasciculations: a correlation with electromyography. Muscle Nerve 1990; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/7\">",
"      Ward SR, Lieber RL. Density and hydration of fresh and fixed human skeletal muscle. J Biomech 2005; 38:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/8\">",
"      Hodges PW, Pengel LH, Herbert RD, Gandevia SC. Measurement of muscle contraction with ultrasound imaging. Muscle Nerve 2003; 27:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/9\">",
"      Reimers CD, Finkenstaedt M. Muscle imaging in inflammatory myopathies. Curr Opin Rheumatol 1997; 9:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/10\">",
"      Schwennicke A, Bargfrede M, Reimers CD. Clinical, electromyographic, and ultrasonographic assessment of focal neuropathies. J Neuroimaging 1998; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/11\">",
"      Reimers CD, Schlotter B, Eicke BM, Witt TN. Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. J Neurol Sci 1996; 143:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/12\">",
"      Gunreben G, Bogdahn U. Real-time sonography of acute and chronic muscle denervation. Muscle Nerve 1991; 14:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/13\">",
"      K&uuml;llmer K, Sievers KW, Reimers CD, et al. Changes of sonographic, magnetic resonance tomographic, electromyographic, and histopathologic findings within a 2-month period of examinations after experimental muscle denervation. Arch Orthop Trauma Surg 1998; 117:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/14\">",
"      Zaidman CM, Connolly AM, Malkus EC, et al. Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2010; 20:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/15\">",
"      Pillen S, Arts IM, Zwarts MJ. Muscle ultrasound in neuromuscular disorders. Muscle Nerve 2008; 37:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/16\">",
"      Pillen S, Verrips A, van Alfen N, et al. Quantitative skeletal muscle ultrasound: diagnostic value in childhood neuromuscular disease. Neuromuscul Disord 2007; 17:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/17\">",
"      Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994; 17:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/18\">",
"      Caress JB, Walker FO. The spectrum of ectopic motor nerve behavior: from fasciculations to neuromyotonia. Neurologist 2002; 8:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/19\">",
"      Misawa S, Noto Y, Shibuya K, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology 2011; 77:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/20\">",
"      van Alfen N, Nienhuis M, Zwarts MJ, Pillen S. Detection of fibrillations using muscle ultrasound: diagnostic accuracy and identification of pitfalls. Muscle Nerve 2011; 43:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/21\">",
"      van Baalen A, Stephani U. Fibration, fibrillation, and fasciculation: say what you see. Clin Neurophysiol 2007; 118:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/22\">",
"      Demondion X, Herbinet P, Boutry N, et al. Sonographic mapping of the normal brachial plexus. AJNR Am J Neuroradiol 2003; 24:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/23\">",
"      Walker FO, Cartwright MS, Wiesler ER, Caress J. Ultrasound of nerve and muscle. Clin Neurophysiol 2004; 115:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/24\">",
"      Silvestri E, Martinoli C, Derchi LE, et al. Echotexture of peripheral nerves: correlation between US and histologic findings and criteria to differentiate tendons. Radiology 1995; 197:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/25\">",
"      Brown BS. How safe is diagnostic ultrasonography? Can Med Assoc J 1984; 131:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/26\">",
"      Hough AD, Moore AP, Jones MP. Peripheral nerve motion measurement with spectral Doppler sonography: a reliability study. J Hand Surg Br 2000; 25:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/27\">",
"      Lee CH, Kim TK, Yoon ES, Dhong ES. Correlation of high-resolution ultrasonographic findings with the clinical symptoms and electrodiagnostic data in carpal tunnel syndrome. Ann Plast Surg 2005; 54:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/28\">",
"      Wong SM, Griffith JF, Hui AC, et al. Carpal tunnel syndrome: diagnostic usefulness of sonography. Radiology 2004; 232:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/29\">",
"      Kele H, Verheggen R, Bittermann HJ, Reimers CD. The potential value of ultrasonography in the evaluation of carpal tunnel syndrome. Neurology 2003; 61:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/30\">",
"      Beekman R, Visser LH. Sonography in the diagnosis of carpal tunnel syndrome: a critical review of the literature. Muscle Nerve 2003; 27:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/31\">",
"      Nakamichi KI, Tachibana S. Enlarged median nerve in idiopathic carpal tunnel syndrome. Muscle Nerve 2000; 23:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/32\">",
"      Ochoa J, Fowler TJ, Gilliatt RW. Anatomical changes in peripheral nerves compressed by a pneumatic tourniquet. J Anat 1972; 113:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/33\">",
"      Ochoa J, Danta G, Fowler TJ, Gilliatt RW. Nature of the nerve lesion caused by a pneumatic tourniquet. Nature 1971; 233:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/34\">",
"      Lundborg G, Myers R, Powell H. Nerve compression injury and increased endoneurial fluid pressure: a \"miniature compartment syndrome\". J Neurol Neurosurg Psychiatry 1983; 46:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/35\">",
"      Mackinnon SE, Dellon AL, Hudson AR, Hunter DA. Chronic human nerve compression--a histological assessment. Neuropathol Appl Neurobiol 1986; 12:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/36\">",
"      Dellon AL, Mackinnon SE. Human ulnar neuropathy at the elbow: clinical, electrical, and morphometric correlations. J Reconstr Microsurg 1988; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/37\">",
"      Aziz W, Firrell JC, Ogden L, Breidenbach WC. Blood flow in a chronic entrapment neuropathy model in the rabbit sciatic nerve. J Reconstr Microsurg 1999; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/38\">",
"      El-Karabaty H, Hetzel A, Galla TJ, et al. The effect of carpal tunnel release on median nerve flattening and nerve conduction. Electromyogr Clin Neurophysiol 2005; 45:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/39\">",
"      Erel E, Dilley A, Greening J, et al. Longitudinal sliding of the median nerve in patients with carpal tunnel syndrome. J Hand Surg Br 2003; 28:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/40\">",
"      Beekman R, Wokke JH, Schoemaker MC, et al. Ulnar neuropathy at the elbow: follow-up and prognostic factors determining outcome. Neurology 2004; 63:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/41\">",
"      Beekman R, Van Der Plas JP, Uitdehaag BM, et al. Clinical, electrodiagnostic, and sonographic studies in ulnar neuropathy at the elbow. Muscle Nerve 2004; 30:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/42\">",
"      Park GY, Kim JM, Lee SM. The ultrasonographic and electrodiagnostic findings of ulnar neuropathy at the elbow. Arch Phys Med Rehabil 2004; 85:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/43\">",
"      Caress JB, Becker CE, Cartwright MS, Walker FO. Ultrasound in the diagnosis of ulnar neuropathy at the elbow. J Clin Neuromuscul Dis 2003; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/44\">",
"      Peer S, Harpf C, Willeit J, et al. Sonographic evaluation of primary peripheral nerve repair. J Ultrasound Med 2003; 22:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/45\">",
"      Bodner G, Harpf C, Gardetto A, et al. Ultrasonography of the accessory nerve: normal and pathologic findings in cadavers and patients with iatrogenic accessory nerve palsy. J Ultrasound Med 2002; 21:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/46\">",
"      Bodner G, Buchberger W, Schocke M, et al. Radial nerve palsy associated with humeral shaft fracture: evaluation with US--initial experience. Radiology 2001; 219:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/47\">",
"      Hobson-Webb LD, Walker FO. Traumatic neuroma diagnosed by ultrasonography. Arch Neurol 2004; 61:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/48\">",
"      Kuo YL, Yao WJ, Chiu HY. Role of sonography in the preoperative assessment of neurilemmoma. J Clin Ultrasound 2005; 33:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/49\">",
"      Pedrazzini M, Pogliacomi F, Cusmano F, et al. Bilateral ganglion cyst of the common peroneal nerve. Eur Radiol 2002; 12:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/50\">",
"      Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer 2005; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/51\">",
"      Young NP, Sorenson EJ, Spinner RJ, Daube JR. Clinical and electrodiagnostic correlates of peroneal intraneural ganglia. Neurology 2009; 72:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/52\">",
"      Heinemeyer O, Reimers CD. Ultrasound of radial, ulnar, median, and sciatic nerves in healthy subjects and patients with hereditary motor and sensory neuropathies. Ultrasound Med Biol 1999; 25:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/53\">",
"      Matsuoka N, Kohriyama T, Ochi K, et al. Detection of cervical nerve root hypertrophy by ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 219:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/54\">",
"      Taniguchi N, Itoh K, Wang Y, et al. Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Ultrasound 2000; 28:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/55\">",
"      Beekman R, van den Berg LH, Franssen H, et al. Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy. Neurology 2005; 65:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/56\">",
"      Zaidman CM, Al-Lozi M, Pestronk A. Peripheral nerve size in normals and patients with polyneuropathy: an ultrasound study. Muscle Nerve 2009; 40:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30232/abstract/57\">",
"      Cartwright MS, Walker FO, Griffin LP, Caress JB. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44:346.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14145 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30232=[""].join("\n");
var outline_f29_33_30232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28971393\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971308\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971315\">",
"      TECHNICAL AND HISTORICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971322\">",
"      ULTRASOUND OF NORMAL MUSCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971329\">",
"      Ultrasound of muscle motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971336\">",
"      ULTRASOUND OF DISEASED MUSCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971343\">",
"      Dynamic changes in diseased muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971350\">",
"      ULTRASOUND OF NORMAL NERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971357\">",
"      Normal nerve movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971364\">",
"      ULTRASOUND OF NERVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971372\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971379\">",
"      Other compressive neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28971386\">",
"      Other forms of focal nerve pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20833577\">",
"      Polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28971393\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14145|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/49/28434\" title=\"diagnostic image 1\">",
"      Ultrasound axial image of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/42/23203\" title=\"diagnostic image 2\">",
"      Ultrasound of the tibialis anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/46/15075\" title=\"diagnostic image 3\">",
"      Ultrasound tibialis anterior with foot inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/50/35623\" title=\"diagnostic image 4\">",
"      Ultrasound of the tibialis anterior after polio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/15/25841\" title=\"diagnostic image 5\">",
"      Ultrasound atrophic triceps and deltoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/25/43411\" title=\"diagnostic image 6\">",
"      Ultrasound deltoids post trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/41/25236\" title=\"diagnostic image 7\">",
"      Ultrasound ulnar nerve after elbow fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14145|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 1\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14145|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/57/39839\" title=\"movie 1\">",
"      Ultrasound biceps contraction and relaxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/9/38032\" title=\"movie 2\">",
"      Ultrasound benign fasciculations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/26/10656\" title=\"movie 3\">",
"      Ultrasound normal median nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/12/37056\" title=\"movie 4\">",
"      Ultrasound normal radial nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/7/36991\" title=\"movie 5\">",
"      Ultrasound median nerve movement in axial view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/11/27824\" title=\"movie 6\">",
"      Ultrasound median nerve movement in sagittal view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/22/16751\" title=\"movie 7\">",
"      Ultrasound ulnar nerve at the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/48/35599\" title=\"movie 8\">",
"      Ultrasound persistent median artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/3/30774\" title=\"movie 9\">",
"      Ultrasound traumatic neuroma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_33_30233="Extrarenal manifestations of autosomal dominant polycystic kidney disease";
var content_f29_33_30233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30233/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Vicente E Torres, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30233/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/33/30233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease (ADPKD) is associated with cysts in the kidneys and, in many cases, cysts in the liver and pancreas that can be helpful in confirming the diagnosis. In addition, patients may have a variety of other abnormalities, many of which are consistent with a generalized defect in epithelial cell differentiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracellular matrix function as a primary expression of the genetic abnormality in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major extrarenal complications of ADPKD are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cerebral aneurysms",
"     </li>",
"     <li>",
"      Hepatic and pancreatic cysts",
"     </li>",
"     <li>",
"      Cardiac valve disease",
"     </li>",
"     <li>",
"      Colonic diverticula",
"     </li>",
"     <li>",
"      Abdominal wall and inguinal hernia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malformations of selected vasculature, including intracranial aneurysms and aortic root dilatation (normal diameter &le;35 mm), may be due to altered expression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function of the PKD gene in arterial smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/6\">",
"     6",
"    </a>",
"    ]. Cervicocephalic artery dissections, dolichoectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and central retinal vascular occlusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/9\">",
"     9",
"    </a>",
"    ] have also been associated with ADPKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CEREBRAL ANEURYSM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ruptured cerebral aneurysm, resulting in a subarachnoid or intracerebral hemorrhage, is the most serious complication of polycystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of aneurysms in ADPKD is approximately 5 percent in young adults and increases with age to as high as 20 percent in patients 60 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,3,10-13\">",
"     2,3,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a family history of intracranial aneurysm or subarachnoid hemorrhage appear to be at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,7,13-15\">",
"     2,7,13-15",
"    </a>",
"    ]. Data from two studies, for example, demonstrated asymptomatic intracranial aneurysms in 17 of 78 patients (22 percent) with and 35 of 348 patients (10 percent) without a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. The position of the mutation also may be predictive of intracranial aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysm rupture in ADPKD most often occurs with larger aneurysms, usually before the age of 50",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in patients with poorly controlled hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/12\">",
"     12",
"    </a>",
"    ]. However, both hypertensive stroke and intracerebral hemorrhage are more common than aneurysm rupture in ADPKD.",
"   </p>",
"   <p>",
"    In a review of 77 patients with intracranial aneurysm (71 with previous aneurysm rupture), the following additional characteristics were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One-half of patients had normal renal function",
"     </li>",
"     <li>",
"      The middle cerebral artery was usually involved, but 31 percent had multiple aneurysms",
"     </li>",
"     <li>",
"      Death or severe disability occurred in 48 percent in the 71 patients with a ruptured aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common complaint with a subarachnoid hemorrhage is the acute onset of severe headache, frequently associated with nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .) As an example, a prospective study of 148 patients (not with ADPKD) presenting with sudden and severe headache found subarachnoid hemorrhage in 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediate evaluation is essential in this setting to preserve neurologic function; CT scanning can usually detect both the aneurysm and blood in the subarachnoid space. This test, however, can miss small bleeds; thus, a negative CT scan should be followed in 6 to 12 hours by a lumbar puncture looking for xanthochromia and red cells. Arteriography should be performed if these findings are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In view of the poor prognosis associated with a major subarachnoid hemorrhage, early diagnosis of symptoms related to growth or change of an intracranial aneurysm is important. As an example, some patients with subarachnoid hemorrhage have warning symptoms of severe headache from a small bleed (also called a warning leak or sentinel bleed), usually occurring within the previous 30 days. However, most first hemorrhages appear to be serious [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue is the natural history of intracerebral aneurysms in patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the better studies evaluated the risk of recurrent aneurysm formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in size of an existing aneurysm among ADPKD patients with a history of either a ruptured or intact intracranial aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/19\">",
"     19",
"    </a>",
"    ]. In this report, 20 ADPKD patients, 11 and 9 of whom had ruptured and intact intracranial aneurysms, respectively, were followed for a mean of approximately 15 years from the time of initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/19\">",
"     19",
"    </a>",
"    ]. All of the patients with ruptured aneurysms and one with an intact aneurysm had undergone surgery at diagnosis.",
"   </p>",
"   <p>",
"    One patient had recurrent subarachnoid hemorrhage and no patient died during the study. On follow-up imaging with MRA or conventional angiography at a mean period of 11.4 years, five patients (25 percent) had a new aneurysm in a different location and two of the same five also had an increase in size of the previously known aneurysm. Ten patients underwent neurosurgery; the discrepancy between the number requiring surgery and the number with intracerebral aneurysm changes was due to the reevaluation and different interpretation of the initial radiographic studies, resulting in surgery in patients initially not thought to be at risk for rupture.",
"   </p>",
"   <p>",
"    When the groups with and without aneurysm changes were compared, no clinical factors were significantly associated with the development of a new aneurysm or an increase in size of an existing aneurysm; this included age at diagnosis, time to restudy, proportion with initially ruptured aneurysm, time of follow-up, time to surgery, and proportion with surgery.",
"   </p>",
"   <p>",
"    The best available data from the general population suggest that the risk of subarachnoid hemorrhage from rupture of small aneurysms (&le;7 mm) is low in patients without a prior subarachnoid hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H13#H13\">",
"     \"Unruptured intracranial aneurysms\", section on 'Natural history of unruptured aneurysms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This observation appears to apply to patients with ADPKD. This was illustrated in a study of 18 patients with ADPKD who had small (&lt;7 mm) asymptomatic intracranial aneurysms on initial screening [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/20\">",
"     20",
"    </a>",
"    ]. At a mean follow-up of eight to nine years, there were no aneurysm ruptures. A larger study from the same institution included 45 saccular aneurysms detected in 38 patients from 36 families. Most were small (median diameter 3.5 mm) and in the anterior circulation (84 percent). Median age at diagnosis was 49 years. During cumulative clinical follow-up of 316 years, no aneurysm ruptured [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role for radiologic screening of asymptomatic patients with ADPKD is unsettled, with time of flight magnetic resonance angiography (MRA) without gadolinium or high-resolution CT angiography (CTA) being the procedures of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/11,13,20,22,23\">",
"     11,13,20,22,23",
"    </a>",
"    ]. Cerebral angiography is invasive and may be associated with an increased risk of cerebral bleeding or stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/11\">",
"     11",
"    </a>",
"    ]. Time-of-flight magnetic resonance angiography does not require gadolinium contrast and can be performed safely at any level of GFR. Administration of gadolinium should be avoided in patients with moderate to severe renal disease because of the risk of nephrogenic systemic fibrosis.",
"   </p>",
"   <p>",
"    The problems with screening include the usual detection of small aneurysms (less than 7 mm in diameter) that are at low risk for rupture (",
"    <a class=\"graphic graphic_figure graphicRef63534 \" href=\"UTD.htm?42/27/43454\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and an appreciable risk of severe neurologic complications following elective aneurysm surgery or endovascular treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/11,22,24,25\">",
"     11,22,24,25",
"    </a>",
"    ]. The risk of intervention was best illustrated in an observational study from the International Study of Unruptured Intracranial Aneurysms in which 1917 patients underwent open surgical repair and 451 endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/25\">",
"     25",
"    </a>",
"    ]. Although these patients did not have ADPKD, one would expect the results to be similar.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1591 patients who underwent surgery and had no prior history of aneurysm rupture, the rate of surgery-related death or poor neurologic outcomes was 13.7 percent at 30 days and 12.6 percent at one year (the lower value at one year reflects neurologic recovery in some patients). Similar outcomes were noted in 326 patients who had a history of prior subarachnoid hemorrhage from a different site.",
"     </li>",
"     <li>",
"      Among 409 patients who underwent endovascular repair and had no prior history of aneurysm rupture, the rate of therapy-related death or poor neurologic outcomes was 9.3 percent at 30 days and 9.8 percent at one year.",
"     </li>",
"     <li>",
"      The risk of an adverse outcome after surgery was importantly affected by patient age, increasing progressively from 6 percent between the ages of 40 and 49 to 30 percent at age 70 or higher. Other risk factors identified on multivariate analysis included aneurysm size &gt;12 mm and location in the posterior circulation. These two risk factors, but not increasing age, were important in patients undergoing endovascular repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Follow-up testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data concerning the role of follow-up radiographic monitoring in patients found to have small aneurysms at screening.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report performed 30 magnetic resonance angiograms in 10 such patients over a mean interval of 30 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/26\">",
"       26",
"      </a>",
"      ]. No change in aneurysm size or the development of new aneurysms was noted. Serial studies in three patients with symptomatic aneurysms also failed to detect de novo aneurysm formation over an eight year period.",
"     </li>",
"     <li>",
"      In the previously mentioned study of 20 patients with a history of ruptured (11 patients) or asymptomatic (9 patients) intracranial aneurysms, the proportion with progressive disease in the intracranial circulation at time of restudy (mean 11.4 years [range of 1.6 to 30.2 years] from the time of initial diagnosis) was less among patients with asymptomatic aneurysms compared to those with a history of ruptured aneurysms (11 versus 36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/19\">",
"       19",
"      </a>",
"      ]. However, the number of patients was small and this difference was not statistically significant.",
"     </li>",
"     <li>",
"      In the previously mentioned study, 38 patients with 45 aneurysms detected by presymptomatic screening had a cumulative MRA follow-up of 243 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/21\">",
"       21",
"      </a>",
"      ] . One de novo aneurysm was detected and increased in size from 2 to 4.4 mm over 144 months and two previously detected aneurysms grew from 4.5 to 5.9 mm and 4.7 to 6.2 mm after 69 and 184 months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is the role of follow-up radiographic monitoring in patients with ADPKD who have initially negative aneurysm screening studies. This was evaluated in a prospective report of 76 patients with an initially negative radiographic imaging procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/27\">",
"     27",
"    </a>",
"    ]. At follow-up imaging at a mean period of 9.8 years, two patients (2.6 percent) were found to have a new intracranial aneurysm, but only one occurrence was clinically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated by these observations, the risk-benefit ratio of screening asymptomatic patients is uncertain. At present, routine screening is recommended only for high-risk patients, such as those with a previous rupture, a positive family history of an intracerebral bleed or intracranial aneurysm, warning symptoms, a high-risk occupation in which loss of consciousness would place the patient or others at extreme risk, and prior to surgery that is likely to be associated with hemodynamic instability with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,4,14\">",
"     2,4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who have aneurysms that do not require immediate surgical intervention, we suggest follow-up monitoring with MRA or CTA annually for two to three years, and every two to five years thereafter if the aneurysm is clinically and radiographically stable. However, it is not unreasonable to reimage newly detected small aneurysms at six months, since there is evidence that newly formed small aneurysms may be at higher risk of rupture than older more stable aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H15#H15\">",
"     \"Unruptured intracranial aneurysms\", section on 'Hypothesis of growth and rupture'",
"    </a>",
"    .) Longer reimaging intervals are certainly appropriate if the six month study shows no significant change.",
"   </p>",
"   <p>",
"    Among patients with initially negative radiographic studies, we rescreen every five years among those with a family history of intracerebral bleed or cerebrovascular accident (CVA). In those with initially negative studies and no family history of CVA or bleed, the role of additional screening is unclear, with some clinicians continuing to screen every five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications for intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysms of any size associated with symptoms or those having high risk features based on size, location and shape, should undergo treatment by microsurgical or endovascular repair, since some lesions can have a high risk of rupture. The selection of patients who have asymptomatic aneurysms that require surgical intervention is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H22#H22\">",
"     \"Unruptured intracranial aneurysms\", section on 'Management of unruptured aneurysms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H30#H30\">",
"     \"Unruptured intracranial aneurysms\", section on 'Whom to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with known unruptured aneurysms who are managed conservatively should be instructed to avoid uncontrolled hypertension, smoking, heavy alcohol consumption, stimulant medications, illicit drugs, and excessive straining and Valsalva maneuvers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Safety of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADPKD may require chronic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for disorders such as deep vein thrombosis or atrial fibrillation. In most such patients, it will not be known if there is or is not an intracranial aneurysm. Although data are limited, studies in patients with unruptured intracranial aneurysms (most often not related to ADPKD) have concluded that it is not known if warfarin increases the risk of intracranial bleeding but, if rupture occurs, anticoagulation increases the severity of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is reasonable to screen such patients for a cerebral aneurysm. Patients with an aneurysm should be told about the relative risks and benefits of anticoagulation and evaluated for possible nonpharmacologic therapies (eg, inferior vena cava filter for deep vein thrombosis and radiofrequency ablation for atrial fibrillation). Those without an aneurysm probably have a risk of cerebral hemorrhage from anticoagulation that is similar to the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEPATIC CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with renal cysts, the prevalence of hepatic cysts increases with age. Earlier studies reported a prevalence of approximately 10 to 20 percent below the age of 30, and 50 to 70 percent over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. However, in a study of 230 patients with ADPKD between the ages of 15 and 46 years, MRI identified hepatic cysts in 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/31\">",
"     31",
"    </a>",
"    ]. Extents of the cystic disease in the kidney and the liver are only weakly correlated suggesting that, in addition to the PKD mutations, other factors distinct for each organ are important for the development and progression of polycystic kidney and polycystic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic cysts occurring in ADPKD are different from autosomal dominant polycystic liver disease (ADPLD). Patients with ADPLD may have no or only few renal cysts, but mice with knockout of either of the two known ADPLD genes have polycystic kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and management of cystic lesions of the liver\", section on 'Polycystic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the overall prevalence of a polycystic liver in patients with ADPKD is similar in men and women, women may develop cysts at an earlier age, and massive cysts occur almost exclusively in women, particularly those who have had several pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/28,29,31\">",
"     28,29,31",
"    </a>",
"    ]. Such acceleration of hepatic growth may be due to an underlying sensitivity of the cysts to female steroid hormones. Consistent with this hypothesis is the observation that postmenopausal estrogen may be associated with selective enlargement of hepatic cysts as well as the hepatic parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients remain asymptomatic with preserved hepatic function. However, patients rarely develop pain (which may require decompression of the cyst if it is persistent and severe)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyst infection (which requires therapy with an antimicrobial, such as a fluoroquinolone, that can penetrate the cyst and, in some cases, percutaneous drainage) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,30,35\">",
"     2,30,35",
"    </a>",
"    ]. Acute pain usually results from cyst infection or hemorrhage, and rarely from rupture or torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/30\">",
"     30",
"    </a>",
"    ]. Radionuclide imaging and, more recently,",
"    <sup>",
"     18",
"    </sup>",
"    F-fluorodeoxyglucose positron emission tomography scanning have been used for diagnosis of hepatic cyst infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Partial hepatic resection has been attempted with some success in patients with massive symptomatic cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/30,38,39\">",
"     30,38,39",
"    </a>",
"    ]; however, this procedure should be limited to refractory patients and performed only in centers with experience in hepatic surgery. Liver transplantation and combined",
"    <span class=\"nowrap\">",
"     liver/kidney",
"    </span>",
"    transplantation have been performed in patients with severe, symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/40\">",
"     40",
"    </a>",
"    ]. Rarely, invasive management is undertaken for the management of refractory pain. In patients who are not surgical candidates, percutaneous transcatheter hepatic artery embolization may be a treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunosuppressive agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , appears to decrease polycystic liver volume possibly via an antiproliferative effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/42\">",
"     42",
"    </a>",
"    ]. In a retrospective study, liver volume was assessed in seven kidney transplant patients administered",
"    <span class=\"nowrap\">",
"     sirolimus/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"      mycophenolate",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"      prednisone",
"     </a>",
"    </span>",
"    and nine recipients given",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /mycophenolate/prednisone",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/42\">",
"     42",
"    </a>",
"    ]. At 19 months, the sirolimus-based regimen resulted in a decrease in mean liver volume of 12 percent, while the mean liver volume increased by 14 percent in those individuals using a tacrolimus-based regimen. Further data are required to understand the role, if any, of sirolimus in this setting.",
"   </p>",
"   <p>",
"    Somatostatin may reduce renal and liver cyst fluid accumulation among patients with PKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H21#H21\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Somatostatin'",
"    </a>",
"    .) There are insufficient data to support the use of these modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PANCREATIC CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cysts occur in approximately 7 to 10 percent of patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. They have also been demonstrated in a mouse model of ADPKD due to both PKD1 and PKD2 gene mutations, which are responsible for almost all cases of ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Associations with intraductal papillary mucinous neoplasm has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARDIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular abnormalities of unclear clinical significance can be detected by cardiac ultrasonography in 25 to 30 percent of patients with ADPKD, most often mild mitral valve prolapse and aortic regurgitation; less frequent lesions include mitral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,53-56\">",
"     2,53-56",
"    </a>",
"    ]. Generalized abnormalities in collagen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracellular matrix may be responsible for the valve disease in ADPKD; aortic regurgitation, for example, may result from dilatation of the aortic root and annulus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients are asymptomatic and the incidence of audible murmurs is substantially lower than abnormalities on ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,54\">",
"     2,54",
"    </a>",
"    ]. Nevertheless, the lesions may progress over time and become severe enough to require valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/53\">",
"     53",
"    </a>",
"    ]. Antimicrobial prophylaxis also may be prudent, particularly in patients with audible murmurs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that polycystic kidney disease may also be associated with an increased incidence of coronary aneurysms and coronary artery dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one study, for example, the prevalence of coronary aneurysms (defined as an increased diameter of 50 percent or more or pathologic ectasia) was evaluated in 30 patients with ADPKD and in the same number of controls with similar degrees of renal dysfunction and equivalent demographic characteristics but without ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/59\">",
"     59",
"    </a>",
"    ]. Both groups underwent coronary angiography for conventional clinical indications. Aneurysms were present in four ADPKD and two control patients, while ectatic lesions were detected in five ADPKD, but no control individuals. Coronary artery dissection has been described in isolated case reports.",
"   </p>",
"   <p>",
"    Asymptomatic pericardial effusions appear to occur at increased frequency in patients with ADPKD. This was best shown in a retrospective analysis from the Mayo Clinic in which the presence and severity of pericardial effusions were analyzed by CT among 60 patients with ADPKD (mean serum creatinine concentration 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [160",
"    <span class=\"nowrap\">",
"     &micro;mol/liter]),",
"    </span>",
"    100 patients with CKD not due to ADPKD (mean serum creatinine concentration 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [160",
"    <span class=\"nowrap\">",
"     &micro;mol/liter]),",
"    </span>",
"    and 100 healthy kidney donors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/60\">",
"     60",
"    </a>",
"    ]. A pericardial effusion was found in 35, 9, and 4 percent of ADPKD patients, patients with CKD, and healthy donors, respectively. A moderate to high effusion severity score was noted in nearly 50 percent of patients with ADPKD and an effusion, but in none of the others. Despite the size of these effusions, they were generally well tolerated and clinically inconsequential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIVERTICULA AND HERNIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic diverticula and abdominal wall and inguinal hernias are seen with increased frequency in patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,61-65\">",
"     2,61-65",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonic diverticula are found in many ADPKD patients on maintenance dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/61\">",
"       61",
"      </a>",
"      ], but may not occur with increased frequency in those without end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/63\">",
"       63",
"      </a>",
"      ]. Symptoms that may occur include abdominal pain (that may be difficult to distinguish from the pain induced by the renal cysts), diarrhea, and heme-positive stools. The incidence of complications, such as colonic perforation, appears to be higher than seen with diverticular disease in patients without polycystic kidney disease, and may be increased following transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/2,61\">",
"       2,61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"       \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diverticular disease of the duodenum presenting with nausea, vomiting, abdominal pain, malabsorption or bile or pancreatic duct obstruction may also be associated with ADPKD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/66\">",
"       66",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Abdominal wall hernias were, in one series, found in 45 percent of patients with ADPKD; the incidence was much higher than in patients with other causes of chronic renal failure or general surgery patients (8 and 4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/64\">",
"       64",
"      </a>",
"      ]. Patients with ADPKD treated with continuous ambulatory peritoneal dialysis are also at increased risk for an indirect inguinal hernia, probably due to a high frequency of a patent processus vaginalis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"       \"Abdominal hernias in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between abdominal aortic aneurysms and ADPKD has been proposed. However, a study that compared 139 patients with ADPKD and 149 controls was unable to demonstrate by ultrasonography an increase in either aortic diameter or the incidence of aneurysm formation in the patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/67\">",
"     67",
"    </a>",
"    ]. Although aortic aneurysms do not appear to be an intrinsic feature of ADPKD, there may be some increase in risk in patients with uncontrolled hypertension.",
"   </p>",
"   <p>",
"    Seminal vesicles cysts are present in 40 percent of male ADPKD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Seminal vesicle cysts rarely result in infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/71\">",
"     71",
"    </a>",
"    ]. Defective sperm motility is another cause of male infertility in ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Arachnoid membrane cysts occur in 8 percent and are usually an asymptomatic incidental finding [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. They may increase the risk for subdural hematomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Spinal meningeal diverticula may occur with increased frequency and rarely present with intracranial hypotension due to cerebrospinal fluid leak [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/78\">",
"     78",
"    </a>",
"    ]. A review of CT scans revealed a threefold-increased prevalence of bronchiectasis in ADPKD patients compared to a control population (37 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There does not appear to be an enhanced risk of ovarian cysts among women with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30233/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728528\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major extrarenal complications of ADPKD include cerebral aneurysms, hepatic and pancreatic cysts, cardiac valve disease, colonic diverticula, and abdominal wall and inguinal hernias. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A ruptured cerebral aneurysm, resulting in a subarachnoid or intracerebral hemorrhage, is the most serious complication of polycystic kidney disease. Aneurysms occur in approximately 5 to 20 percent of patients with ADPKD. Patients with a family history of intracranial aneurysm or subarachnoid hemorrhage appear to be at greatest risk. Aneurysm rupture in ADPKD most often occurs with larger aneurysms, usually before the age of 50",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in patients with poorly controlled hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cerebral aneurysm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role for radiologic screening for cerebral aneurysm of asymptomatic patients with ADPKD is unsettled. Routine screening is recommended only for high-risk patients, such as those with a previous rupture, a positive family history of an intracerebral bleed or intracranial aneurysm, warning symptoms, a high-risk occupation in which loss of consciousness would place the patient or others at extreme risk, and prior to surgery that is likely to be associated with hemodynamic instability with hypertension. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening modalities for cerebral aneurysm include high-resolution CT angiography (CTA) or time-of-flight magnetic resonance angiography (MRA). Time-of-flight magnetic resonance angiography does not require gadolinium contrast and can be performed safely at any level of GFR. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aneurysms of any size associated with symptoms or those having high risk features based on size, location and shape, should undergo treatment by microsurgical or endovascular repair, since some lesions can have a high risk of rupture. The selection of patients who have asymptomatic aneurysms that require immediate surgical intervention is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H22#H22\">",
"       \"Unruptured intracranial aneurysms\", section on 'Management of unruptured aneurysms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H30#H30\">",
"       \"Unruptured intracranial aneurysms\", section on 'Whom to treat'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who do not require surgical intervention, we suggest follow-up monitoring with CTA or MRA annually for two to three years, and every two to five years thereafter if the aneurysm is clinically and radiographically stable. However, it is not unreasonable to reimage newly detected small aneurysms at six months, since there is evidence that newly formed small aneurysms may be at higher risk of rupture than older more stable aneurysms. Among patients with initially negative radiographic studies, we rescreen every five years among those with a family history of aneurysm, intracerebral bleed or cerebrovascular accident (CVA). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most patients remain asymptomatic with preserved hepatic function, some develop pain (which may require decompression of the cyst if it is persistent and severe)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyst infection. Pancreatic cysts may also occur, though less commonly than hepatic cysts. Cardiac manifestations of ADPKD include valvular abnormalities, coronary aneurysms and asymptomatic pericardial effusions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Hepatic cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/1\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease--more than a renal disease. Am J Kidney Dis 1990; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/2\">",
"      Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int 1994; 46:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/3\">",
"      Watson ML. Complications of polycystic kidney disease. Kidney Int 1997; 51:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/4\">",
"      Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/5\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/6\">",
"      Griffin MD, Torres VE, Grande JP, Kumar R. Vascular expression of polycystin. J Am Soc Nephrol 1997; 8:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/7\">",
"      Graf S, Schischma A, Eberhardt KE, et al. Intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2002; 17:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/8\">",
"      Schievink WI, Torres VE, Wiebers DO, Huston J 3rd. Intracranial arterial dolichoectasia in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/9\">",
"      Qian Q, Younge BR, Torres VE. Retinal arterial and venous occlusions in patients with ADPKD. Nephrol Dial Transplant 2007; 22:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/10\">",
"      Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011; 42:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/11\">",
"      Chapman AB, Rubinstein D, Hughes R, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/12\">",
"      Schievink WI, Torres VE, Piepgras DG, Wiebers DO. Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1992; 3:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/13\">",
"      Huston J 3rd, Torres VE, Sulivan PP, et al. Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/14\">",
"      Chauveau D, Pirson Y, Verellen-Dumoulin C, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 1994; 45:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/15\">",
"      Belz MM, Hughes RL, Kaehny WD, et al. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2001; 38:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/16\">",
"      Rossetti S, Chauveau D, Kubly V, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003; 361:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/17\">",
"      Linn FH, Wijdicks EF, van der Graaf Y, et al. Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. Lancet 1994; 344:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/18\">",
"      Chauveau D, Sirieix ME, Schillinger F, et al. Recurrent rupture of intracranial aneurysms in autosomal dominant polycystic kidney disease. BMJ 1990; 301:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/19\">",
"      Belz MM, Fick-Brosnahan GM, Hughes RL, et al. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 63:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/20\">",
"      Gibbs GF, Huston J 3rd, Qian Q, et al. Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int 2004; 65:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/21\">",
"      Irazabal MV, Huston J 3rd, Kubly V, et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/22\">",
"      Wiebers DO, Torres VE. Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/23\">",
"      Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002; 13:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/24\">",
"      Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Engl J Med 1998; 339:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/25\">",
"      Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/26\">",
"      Huston J 3rd, Torres VE, Wiebers DO, Schievink WI. Follow-up of intracranial aneurysms in autosomal dominant polycystic kidney disease by magnetic resonance angiography. J Am Soc Nephrol 1996; 7:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/27\">",
"      Schrier RW, Belz MM, Johnson AM, et al. Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten-year follow-up. J Am Soc Nephrol 2004; 15:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/28\">",
"      Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/29\">",
"      Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993; 22:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/30\">",
"      Chauveau D, Fakhouri F, Gr&uuml;nfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 2000; 11:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/31\">",
"      Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/32\">",
"      Torres VE, Chapman AB, Perrone RD, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012; 81:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/33\">",
"      Fedeles SV, Tian X, Gallagher AR, et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet 2011; 43:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/34\">",
"      Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997; 26:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/35\">",
"      Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/36\">",
"      Bleeker-Rovers CP, de S&eacute;vaux RG, van Hamersvelt HW, et al. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2003; 41:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/37\">",
"      Jouret F, Lhommel R, Beguin C, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/38\">",
"      Newman KD, Torres VE, Rakela J, Nagorney DM. Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure. Ann Surg 1990; 212:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/39\">",
"      Schnelldorfer T, Torres VE, Zakaria S, et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009; 250:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/40\">",
"      Kirchner GI, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/41\">",
"      Takei R, Ubara Y, Hoshino J, et al. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2007; 49:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/42\">",
"      Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/43\">",
"      Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/44\">",
"      Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/45\">",
"      Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/46\">",
"      Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27:3532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/47\">",
"      Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/48\">",
"      Higashihara E, Aso Y, Shimazaki J, et al. Clinical aspects of polycystic kidney disease. J Urol 1992; 147:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/49\">",
"      Malka D, Hammel P, Vilgrain V, et al. Chronic obstructive pancreatitis due to a pancreatic cyst in a patient with autosomal dominant polycystic kidney disease. Gut 1998; 42:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/50\">",
"      Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/51\">",
"      Kim I, Ding T, Fu Y, et al. Conditional mutation of Pkd2 causes cystogenesis and upregulates beta-catenin. J Am Soc Nephrol 2009; 20:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/52\">",
"      Sato Y, Mukai M, Sasaki M, et al. Intraductal papillary-mucinous neoplasm of the pancreas associated with polycystic liver and kidney disease. Pathol Int 2009; 59:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/53\">",
"      Leier CV, Baker PB, Kilman JW, Wooley CF. Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med 1984; 100:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/54\">",
"      Hossack KF, Leddy CL, Johnson AM, et al. Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 1988; 319:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/55\">",
"      Timio M, Monarca C, Pede S, et al. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred. Clin Nephrol 1992; 37:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/56\">",
"      Lumiaho A, Ik&auml;heimo R, Miettinen R, et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 2001; 38:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/57\">",
"      Itty CT, Farshid A, Talaulikar G. Spontaneous coronary artery dissection in a woman with polycystic kidney disease. Am J Kidney Dis 2009; 53:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/58\">",
"      Basile C, Lucarelli K, Langialonga T. Spontaneous coronary artery dissection: One more extrarenal manifestation of autosomal dominant polycystic kidney disease? J Nephrol 2009; 22:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/59\">",
"      Hadimeri H, Lamm C, Nyberg G. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/60\">",
"      Qian Q, Hartman RP, King BF, Torres VE. Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/61\">",
"      Scheff RT, Zuckerman G, Harter H, et al. Diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Ann Intern Med 1980; 92:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/62\">",
"      Gabow PA, Ikl&eacute; DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. Ann Intern Med 1984; 101:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/63\">",
"      Sharp CK, Zeligman BE, Johnson AM, et al. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 1999; 34:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/64\">",
"      Morris-Stiff G, Coles G, Moore R, et al. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg 1997; 84:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/65\">",
"      Modi KB, Grant AC, Garret A, Rodger RS. Indirect inguinal hernia in CAPD patients with polycystic kidney disease. Adv Perit Dial 1989; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/66\">",
"      Kumar S, Adeva M, King BF, et al. Duodenal diverticulosis in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2006; 21:3576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/67\">",
"      Torra R, Nicolau C, Badenas C, et al. Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1996; 7:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/68\">",
"      Alpern MB, Dorfman RE, Gross BH, et al. Seminal vesicle cysts: association with adult polycystic kidney disease. Radiology 1991; 180:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/69\">",
"      Danaci M, Akpolat T, Batemir M, et al. The prevalence of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1998; 13:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/70\">",
"      Torra R, Sarquella J, Calabia J, et al. Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2008; 3:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/71\">",
"      Li Vecchi M, Cianfrone P, Damiano R, Fuiano G. Infertility in adults with polycystic kidney disease. Nephrol Dial Transplant 2003; 18:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/72\">",
"      Okada H, Fujioka H, Tatsumi N, et al. Assisted reproduction for infertile patients with 9 + 0 immotile spermatozoa associated with autosomal dominant polycystic kidney disease. Hum Reprod 1999; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/73\">",
"      Fang S, Baker HW. Male infertility and adult polycystic kidney disease are associated with necrospermia. Fertil Steril 2003; 79:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/74\">",
"      Schievink WI, Huston J 3rd, Torres VE, Marsh WR. Intracranial cysts in autosomal dominant polycystic kidney disease. J Neurosurg 1995; 83:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/75\">",
"      Alehan FK, G&uuml;rakan B, Aildere M. Familial arachnoid cysts in association with autosomal dominant polycystic kidney disease. Pediatrics 2002; 110:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/76\">",
"      Wijdicks EF, Torres VE, Schievink WI. Chronic subdural hematoma in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/77\">",
"      Abderrahim E, Hedri H, L&acirc;abidi J, et al. Chronic subdural haematoma and autosomal polycystic kidney disease: report of two new cases. Nephrology (Carlton) 2004; 9:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/78\">",
"      Schievink WI, Torres VE. Spinal meningeal diverticula in autosomal dominant polycystic kidney disease. Lancet 1997; 349:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/79\">",
"      Driscoll JA, Bhalla S, Liapis H, et al. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008; 133:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/80\">",
"      Stamm ER, Townsend RR, Johnson AM, et al. Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30233/abstract/81\">",
"      Heinonen PK, Vuento M, Maunola M, Ala-Houhala I. Ovarian manifestations in women with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2002; 40:504.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1679 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-6DA085BC69-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30233=[""].join("\n");
var outline_f29_33_30233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H728528\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CEREBRAL ANEURYSM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Follow-up testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications for intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Safety of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEPATIC CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PANCREATIC CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARDIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIVERTICULA AND HERNIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728528\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1679|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43454\" title=\"figure 1\">",
"      Frequency of intracranial aneurysm rupture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=related_link\">",
"      Diagnosis and management of cystic lesions of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_33_30234="Molecular genetics of colorectal cancer";
var content_f29_33_30234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular genetics of colorectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Paula M Calvert, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Harold Frucht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/33/30234/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/33/30234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a common disease. Approximately 142,820 new cases are diagnosed each year in the United States (US), of which 102,480 originate in the colon and the rest in the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/1\">",
"     1",
"    </a>",
"    ]. Annually, about 52,390 Americans die of CRC, accounting for approximately 9 percent of all cancer deaths; in the US, CRC ranks third in both incidence and cause of cancer death in both men and women. Global, country-specific data on incidence and mortality are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The risk factors for CRC are both environmental and inherited. The mode of presentation of CRC follows one of three patterns that are reflective of these differing risk factors: sporadic, inherited, and familial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic disease, in which there is no family history, accounts for approximately 70 percent of all CRCs. It is most common over the age of 50, and dietary and environmental factors have been etiologically implicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"       \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fewer than 10 percent of patients have a true inherited predisposition to CRC, and these cases are subdivided according to whether or not colonic polyps are a major disease manifestation. The diseases with polyposis include familial adenomatous polyposis (FAP), MUTYH associated polyposis (MAP), and the hamartomatous polyposis syndromes (eg, Peutz-Jeghers, juvenile polyposis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/2\">",
"       2",
"      </a>",
"      ]), while those without polyposis are referred to as hereditary nonpolyposis CRC (HNPCC, Lynch syndrome). These conditions are all associated with a high risk of developing CRC. In many cases, the causative genetic mutation has been identified and a test is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"       \"Overview of Peutz-Jeghers syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The third and least well understood pattern is known as \"familial\" CRC, which accounts for up to 25 percent of cases. Affected patients have a family history of CRC, but the pattern is not consistent with one of the inherited syndromes described above. Individuals from these families are at increased risk of developing CRC, although the risk is not as high as with the inherited syndromes. Having a single affected first-degree relative (ie, parent, child, sibling) increases the risk of developing CRC 1.7-fold over that of the general population. The risk is further increased if two first-degree relatives have CRC or if the index case is diagnosed before age 55. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"       \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some of these patients may have familial colorectal cancer type X, in which clinical criteria are met for HNPCC, but in the absence of an identified germline mutation in one of the mismatch repair genes, the genetic hallmark of HNPCC [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the term &ldquo;familial&rdquo; colorectal cancer syndrome is probably a misnomer as it is likely that these patients have a currently unidentified inherited genetic mutation.",
"      <br/>",
"      <br/>",
"      In general, the mechanisms underlying familial clustering of CRC in the absence of a discernible inherited syndrome remain incompletely understood. (See",
"      <a class=\"local\" href=\"#H1231983740\">",
"       'Familial CRC without a discernible inherited syndrome'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our level of understanding of the molecular events underlying CRC is far greater than for other common solid tumors. Specific germline mutations are responsible for the inherited CRC syndromes, while a stepwise accumulation of somatic mutations is thought to underlie most sporadic cases. In contrast, the genetic abnormalities underlying &ldquo;familial&rdquo; CRC remain incompletely understood.",
"   </p>",
"   <p>",
"    This topic will review the major genetic aspects of colorectal carcinogenesis, with particular emphasis on sporadic CRC. Inherited conditions that significantly increase the risk of CRC (eg, FAP and HNPCC) and the role of genetic testing and screening for patients with an inherited predisposition are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS OF CRC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific genetic changes are thought to drive the transformation from normal colonic epithelium to invasive cancer. Genetic mutations can be inherited or acquired. Any genetic mutation that occurs at or before fertilization of the ovum is termed a germline mutation and can be transmitted from parent to offspring as an inherited defect. If the mutation occurs spontaneously in the sperm, ovum, or zygote, the affected person's parents do not manifest the cancer phenotype, but future progeny may inherit the de novo mutation. More commonly, a spontaneous mutation appears in a cell during the growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    development of a particular tissue or organ; this is called a somatic mutation. Because these mutations often confer a selective growth advantage, they result in preferential proliferation of the cell containing the mutated genetic material (clonal evolution) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clonal nature of tumors is a critical feature of the somatic",
"    <span class=\"nowrap\">",
"     mutation/clonal",
"    </span>",
"    evolution theory of human carcinogenesis. According to this model, the growth advantage acquired by a single mutated cell allows its progeny to outnumber those of neighboring cells. From within this clonal population, a single cell acquires a second mutation, providing an additional growth advantage that allows further clonal expansion. Subsequent waves of clonal expansion are driven by the sequential acquisition of more mutations, further cellular disorganization, and eventually the ability to invade and metastasize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The adenoma-carcinoma sequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most human CRCs are thought to arise from adenomas (adenomatous polyps) that become dysplastic (",
"    <a class=\"graphic graphic_figure graphicRef56774 \" href=\"UTD.htm?23/13/23775\">",
"     figure 1",
"    </a>",
"    ). Adenomatous polyps form in the colon when normal mechanisms regulating epithelial renewal are disrupted. Surface cells lining the intestine are continuously lost into the bowel lumen due to apoptosis and exfoliation, and must be continuously replaced. Typically, proliferation occurs exclusively at the crypt base. As cells move towards the luminal surface, they cease proliferating and terminally differentiate. This ordered process is increasingly disrupted as adenomas increase in size, become dysplastic, and eventually attain invasive potential.",
"   </p>",
"   <p>",
"    The hypothesis that invasive CRCs develop from intermediate precancerous precursors is supported by pathologic, epidemiologic, and observational clinical data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the patient with colonic polyps\", section on 'Clinical presentation and natural history'",
"    </a>",
"    .) Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early carcinomas are frequently seen within large adenomatous polyps, and areas of adenomatous change can often be found surrounding human CRCs.",
"     </li>",
"     <li>",
"      Adenomas and carcinomas are found in similar distributions throughout the large bowel, and adenomas are typically observed 10 to 15 years prior to the onset of cancer in both sporadic and familial cases.",
"     </li>",
"     <li>",
"      In animal models, adenomas develop before carcinomas, and carcinomas develop exclusively in adenomatous tissue.",
"     </li>",
"     <li>",
"      The ability to reduce the incidence of CRC through removal of polyps has been shown in controlled trials in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the patient with colonic polyps\", section on 'Risk factors for high-grade dysplasia and cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 1990, Fearon and Vogelstein described the molecular basis for CRC as a multistep process in which each accumulated genetic event conferred a selective growth advantage to the colonic epithelial cell [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/4\">",
"     4",
"    </a>",
"    ]. Later studies have served to further refine their hypothesis.",
"   </p>",
"   <p>",
"    According to the Vogelstein model, germline or somatic mutations are required for malignant transformation, and the accumulation of multiple genetic mutations rather than their sequence determines the biological behavior of the tumor (",
"    <a class=\"graphic graphic_figure graphicRef55601 \" href=\"UTD.htm?39/62/40941\">",
"     figure 2",
"    </a>",
"    ). Germline mutations underlie the common inherited syndromes (eg, FAP, HNPCC), while sporadic cancers result from the stepwise accumulation of multiple somatic mutations. Mutations in the APC gene, a feature common to both inherited and sporadic CRCs, occur early in the process, while p53 tumor suppressor gene mutations generally occur late.",
"   </p>",
"   <p>",
"    In addition to point mutations, other genetic changes that are implicated in human tumorigenesis include altered DNA methylation, and gene rearrangements, amplifications, overexpression, and deletions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Serrated polyp pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of colorectal cancers are believed to progress through an adenoma-carcinoma sequence. However, recent evidence increasingly supports the existence of an alternative route for colorectal carcinogenesis through serrated polyps, a group that encompasses a morphological spectrum, including hyperplastic polyps, mixed hyperplastic",
"    <span class=\"nowrap\">",
"     polyp/adenoma,",
"    </span>",
"    and serrated adenomas. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hypermethylation phenotype (CIMP+) pathway'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H26828552#H26828552\">",
"     \"Approach to the patient with colonic polyps\", section on 'Sessile serrated adenoma/polyps and traditional serrated adenomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular pathways to colorectal tumorigenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appear to be at least three molecular pathways leading to colorectal tumorigenesis (",
"    <a class=\"graphic graphic_table graphicRef72239 \" href=\"UTD.htm?28/53/29532\">",
"     table 1",
"    </a>",
"    ): the chromosomal instability (CIN) pathway (which is typified by the inherited condition FAP), the",
"    <span class=\"nowrap\">",
"     mutator-phenotype/DNA",
"    </span>",
"    mismatch repair pathway, which is implicated in the inherited condition HNPCC as well as in a proportion of sporadic CRCs, and the hypermethylation phenotype",
"    <span class=\"nowrap\">",
"     hyperplastic/serrated",
"    </span>",
"    polyp pathway, which is characterized by a high frequency of methylation of some CpG islands (CpG Island hyperMethylation Phenotype [CIMP]-positive) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     The chromosomal instability (APC) pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal instability (CIN) results from \"gain of function\" mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/4\">",
"     4",
"    </a>",
"    ]. These may result either in activation of growth promoting pathways including oncogenes or diminished activity of tumor suppressor genes or apoptotic pathways.",
"   </p>",
"   <p>",
"    These tumors may be inherited (as with familial adenomatous polyposis, FAP), or sporadic, and they are characterized by gross chromosomal abnormalities including deletions, insertions, and loss of heterozygosity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     The mutator phenotype/mismatch repair pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another pathway leading from adenomatous polyps, and probably from serrated adenomas, to invasive cancer has also been described, the mismatch repair pathway. This pathway is involved in CRCs arising in association with the inherited condition HNPCC (Lynch syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The key element of this pathway is dysfunction of DNA mismatch repair (MMR) enzymes, resulting from germline mutations in one of several different DNA mismatch repair genes, most commonly MLH1 or MSH2. Cells with deficient DNA repair capacity due to silencing of MMR genes accumulate DNA errors throughout the genome. The biologic \"footprint\" is the accumulation of abnormalities in short sequences of nucleotide bases that are repeated dozens to hundreds of times within the genome; these are called microsatellites, and the tumors are described as having the phenotype of microsatellite instability (MSI).",
"   </p>",
"   <p>",
"    Besides being the biologic hallmark of HNPCC, MSI is also found in approximately 15 percent of sporadic CRCs. However, in most of these cases, gene silencing is not due to a specific MMR mutation, but to an epigenetic phenomenon, hypermethylation of the gene promoter for the MMR enzyme (usually MLH1), which leads to transcriptional silencing of gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Mismatch repair genes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypermethylation phenotype (CIMP+) pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epigenetic alterations such as DNA hypomethylation and loss of imprinting, as well as DNA hypermethylation can silence the expression of certain genes, including MMR enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. CRCs that have a particularly high frequency of methylation of some CpG islands are referred to as CIMP (for CpG Island hyperMethylation Phenotype) tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/7\">",
"     7",
"    </a>",
"    ]. The defect may result in hypermethylation of the promoter region of MMR enzymes such as MLH1 and silencing of gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activating mutations in the BRAF gene occur almost exclusively in MSI-H, CIMP+ CRCs that do not carry mutations in K-ras [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. HNPCC-related CRCs present only with K-ras and not BRAF mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. BRAF mutations are particularly prevalent in smokers with sporadic CRCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sporadic colorectal cancers with a high degree of microsatellite instability and a high incidence of BRAF mutation are a clinically distinct subgroup that is widely considered to develop from serrated polyps (",
"    <a class=\"graphic graphic_table graphicRef72239 \" href=\"UTD.htm?28/53/29532\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H26828552#H26828552\">",
"     \"Approach to the patient with colonic polyps\", section on 'Sessile serrated adenoma/polyps and traditional serrated adenomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC MOLECULAR ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections will describe the major abnormalities in oncogenes, tumor suppressor genes, MMR genes, and epigenetic phenomena such as DNA hypomethylation and hypermethylation that underlie CRC tumorigenesis, including the importance of each factor in cell cycle control and the molecular and clinical consequences of individual mutations. This discussion is meant as an overview of the molecular pathogenesis of CRC rather than an exhaustive survey, which can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oncogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncogenes are homologs of normal cellular genes that participate in cell growth pathways and cell cycle regulation. A mutational change in an oncogene leads to constitutive activation of the gene, which then results in uncontrolled cellular proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Because the normal gene function is activated, these are referred to as gain of function mutations.",
"   </p>",
"   <p>",
"    Among the oncogenes implicated in sporadic CRC are ras, src, c-myc and c-erbB-2",
"    <span class=\"nowrap\">",
"     (HER2/neu);",
"    </span>",
"    the most important is ras (",
"    <a class=\"graphic graphic_table graphicRef60613 \" href=\"UTD.htm?42/55/43899\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ras",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ras oncogene exists as three cellular variants, H-ras, K-ras, and N-ras. Although all three oncogenes, when mutated, have the ability to transform normal cells, K-ras is the most frequently mutated in human CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The importance of ras to colorectal tumorigenesis is underscored by the finding that CRC cells in which a mutated ras gene has been removed or replaced lose their ability to form tumors in nude mice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ras oncogenes encode a family of small proteins with homology to G-proteins that regulate cellular signal transduction by acting as a one-way switch for the transmission of extracellular growth signals to the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/29\">",
"     29",
"    </a>",
"    ]. These proteins normally cycle between an inactive GDP-bound state and an active GTP-bound state. Ras mutations, typically point mutations, leave the protein resistant to GTP hydrolysis by GTPase, resulting in a constitutively active GTP-bound protein and a continuous growth stimulus. Posttranslational modification of the ras protein by the enzyme farnesyl transferase is necessary for activation, a fact that has been exploited for therapeutic purposes.",
"   </p>",
"   <p>",
"    Ras mutations are found in up to 50 percent of sporadic CRCs and 50 percent of colonic adenomas larger than 1 cm; they are rarely seen in smaller adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. At least two reports suggest that they are more common in proximal colon cancers than in more distal colorectal primaries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. K-ras has also been implicated in the process of tumor invasion and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of mutations in smaller adenomas suggests that ras mutations are acquired during later adenoma progression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/35\">",
"     35",
"    </a>",
"    ]. However, ras mutations are not limited to dysplastic colonic lesions. Up to 100 percent of nondysplastic aberrant crypt foci (ACF, believed to be the first intermediate between normal colonic mucosa and the adenomatous polyp) and 25 percent of hyperplastic polyps have ras mutations, but their significance is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/25,28,29,36\">",
"     25,28,29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of ras mutations in CRC is of potential clinical relevance for both screening and therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The detection of ras mutations in fecal material is a potentially sensitive screening method for the early diagnosis of CRC [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. However, the addition of ras to a panel of other DNA markers (including APC, p53, BAT26 and L-DNA) does not improve the specificity of fecal genetic testing, and subsequent studies using the entire panel of DNA markers have not been as promising as initial reports suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H194078445#H194078445\">",
"       \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Fecal DNA tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The therapeutic potential of agents that target the ras signal transduction pathway (eg, farnesyl transferase inhibitors) is being explored in patients with CRC whose tumors contain ras mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a ras mutation in CRC is significantly associated with the absence of response to agents targeting the epidermal growth factor receptor (EGFR) such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to oncogenes, tumor suppressor genes normally have an inhibitory influence on the cell cycle. Once these genes are deleted or their function reduced, normal control mechanisms are no longer operative, and growth proceeds unchecked. At the cellular level, tumor suppressor genes act in a recessive fashion, meaning that the function of the normal protein is lost only when both copies (alleles) of the gene are inactivated by point mutations, rearrangements, or deletions.",
"   </p>",
"   <p>",
"    Tumor suppressor genes were first described by Knudson in the context of childhood retinoblastoma (RB), which is caused by mutational inactivation of the retinoblastoma (RB1) gene, and presents either as hereditary or sporadic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A \"two hit\" model was proposed to explain the different clinical features of these two presentations (",
"    <a class=\"graphic graphic_figure graphicRef73602 \" href=\"UTD.htm?27/30/28131\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of retinoblastoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inherited form of RB requires a germline mutation that can be either inherited or de novo (ie, the result of a new germline mutation), plus a second somatic mutation, occurring later in development, that affects the remaining RB1 allele within retinal cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/19,40\">",
"       19,40",
"      </a>",
"      ]. Affected individuals are at risk for multifocal and bilateral tumors.",
"     </li>",
"     <li>",
"      By contrast, in the nonhereditary form of RB, both allelic mutations arise spontaneously in a single retinal cell (ie, both are somatic mutations). The resulting phenotype is that of a unifocal, unilateral tumor that presents at a later age than the inherited variant and without heritable transmission to later offspring [",
"      <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first molecular evidence for the involvement of tumor suppressor genes in CRC came from the study of allelic loss, in which large chromosomal deletions were detected using polymorphic markers that distinguish the two alleles present in the germline. When comparing tumor alleles with those present in normal tissue, deletions were identified as \"loss of heterozygosity\" or LOH.",
"   </p>",
"   <p>",
"    In early studies of CRC, LOH for chromosomes 5q, 8p, 17p, or 18q was detected in 36, 50, 73, and 75 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/30,42\">",
"     30,42",
"    </a>",
"    ]. Presumptive tumor suppressor genes were subsequently identified on 5q (the APC gene), 18q (the deleted in colon cancer [DCC] gene, and the SMAD4 and SMAD2 genes), and 17p (the p53 gene).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     APC gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most critical gene in the early development of CRC is the APC tumor suppressor gene. Somatic mutations in both alleles are present in 80 percent of sporadic CRCs, and a single germline mutation in this gene is responsible for FAP, a dominantly inherited syndrome characterized by the development of hundreds to thousands of colorectal polyps by the second or third decade of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link&amp;anchor=H547090028#H547090028\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A germline APC mutation is also thought to contribute to the development of familial CRC in Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/19,43,44\">",
"     19,43,44",
"    </a>",
"    ]. The mutation is found in 6 percent of all persons of Ashkenazi Jewish descent, but in a higher frequency of Ashkenazi Jews with both a personal and family history of CRC (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/43\">",
"     43",
"    </a>",
"    ]. This mutation was previously thought to represent a polymorphism.",
"   </p>",
"   <p>",
"    The recognition of the importance of the APC gene began with genetic studies linking inheritance of the FAP syndrome to chromosome 5q21 and the subsequent identification of germline mutations involving a gene at this locus, the APC gene. The earliest malignant lesions in these patients, dysplastic aberrant crypt foci (microadenomas) and small adenomatous polyps, have lost the second APC allele (through deletion or somatic mutation), suggesting that APC loss is a very early event in CRC tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The function of the APC gene product and the mechanism whereby the abnormal gene promotes tumor formation are beginning to be understood. An important clue was the observation that most sporadic CRCs with normal or wild-type APC had mutations in beta-catenin, a protein involved in the same signaling cascade as APC, the Wnt (Wingless-type) signaling pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. It is now hypothesized that most sporadic CRCs are initiated by activating Wnt pathway mutations, characterized by the stabilization of beta-catenin and constitutive transcription by a",
"    <span class=\"nowrap\">",
"     beta-cetenin/T-cell",
"    </span>",
"    factor (Tcf)-4 complex.",
"   </p>",
"   <p>",
"    The Wnt pathway is an evolutionarily conserved signal transduction pathway that is necessary for embryonic development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. It also plays a central role in supporting intestinal epithelial renewal, an important fact since CRC is thought to originate in the expansion of colonic crypt cells.",
"   </p>",
"   <p>",
"    The basic features of the Wnt signaling pathway are depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72022 \" href=\"UTD.htm?31/17/32019\">",
"     figure 4",
"    </a>",
"    ). The normal APC protein appears to prevent the accumulation of cytosolic and nuclear beta-catenin by mediating its phosphorylation and resultant degradation. The majority of mutations in the APC gene (both germline and somatic) lead to premature truncation of the APC protein and loss of its beta-catenin regulatory domains. Loss of functional APC (as well as mutations in the beta-catenin gene) results in the nuclear accumulation of beta-catenin, which binds and activates the transcription factor Tcf-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is proposed that",
"    <span class=\"nowrap\">",
"     beta-catenin/Tcf-4",
"    </span>",
"    acts as a switch controlling proliferation versus differentiation in the intestinal crypt epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Activation of this pathway prevents the cells from either entering G1 arrest or undergoing terminal differentiation and induces resistance to apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/56\">",
"     56",
"    </a>",
"    ]. The end result is cellular proliferation. In addition, because several other cell signaling pathways converge with the Wnt pathway, it represents a \"final common pathway\" through which multiple abnormalities affecting other cellular signaling pathways may result in the same carcinogenic result.",
"   </p>",
"   <p>",
"    Other mechanisms may also contribute to the tumorigenic potential of APC mutations. Mutations in APC (but not beta-catenin) are associated with chromosomal instability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/57\">",
"     57",
"    </a>",
"    ], predisposing the cell to \"hits\" in other genes that may contribute to tumor progression and malignant transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     p53 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The p53 gene on chromosome 17p is the most commonly mutated gene in human cancer. In about 50 to 70 percent of CRCs, p53 inactivation occurs by a mutation of one allele followed by loss of the remaining wild type gene [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/30,58-61\">",
"     30,58-61",
"    </a>",
"    ]. 17p sequences are lost in as many as 75 percent of CRCs, while they are rarely lost in adenomas and aberrant crypt foci, suggesting that loss of p53 function represents a relatively late event in colorectal tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/4,30,62\">",
"     4,30,62",
"    </a>",
"    ]. In keeping with this hypothesis, a large international study of 3583 CRCs found an increase in the frequency of p53 mutations with advancing disease stage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal \"wild type\" p53 gene produces a DNA-binding protein that acts as a transcriptional activator of growth inhibitory genes. Wild-type p53 may be particularly critical when cells are under stress. Normally, cells arrest their growth in response to DNA damaging agents and other stressors (eg, hypoxia) via",
"    <span class=\"nowrap\">",
"     induction/activation",
"    </span>",
"    of p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Once activated, p53 induces a variety of growth-limiting responses, including cell cycle arrest (in order to facilitate DNA repair), apoptosis, senescence, and differentiation. p53 produces these responses largely by altering the expression of a number of target genes, at least 20 of which have been described as being under transcriptional control of p53. Because of its central role in preventing the propagation of cells with DNA damage, p53 has been referred to as the \"guardian of the genome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although inactivation of the p53 pathway appears to be a late event in the majority of human CRCs, it may represent an earlier event in inflammatory bowel disease-related CRC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H9#H9\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the association of p53 pathway inactivation with CRC, it is unclear why patients with the Li Fraumeni syndrome (a condition caused by a germline mutation in p53 in which patients frequently develop carcinomas, sarcomas, and leukemias) are not at particularly increased risk of developing CRCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of p53 mutations in an individual CRC is of potential clinical significance, prognostically and therapeutically. In many but not all studies, patients whose tumors harbor p53 mutations have worse outcomes and shorter survival than those without such mutations. At least some of the discordant results may be due to the fact that the prognostic influence of p53 abnormalities appears to depend on tumor site, type of mutation, and the use of adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/61\">",
"     61",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link&amp;anchor=H31#H31\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'All other molecular markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From a therapeutic standpoint, it is hoped that p53 may prove to be a highly selective and effective target for intervention. Several new therapies under study for advanced disease specifically target p53-mutant cells, while others seek to correct the p53 mutations directly or to restore the integrity of the p53 pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chromosome 18q: the DCC, SMAD4, and SMAD2 genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with p53 and the APC gene, the first evidence of a tumor suppressor gene on chromosome 18q came from studies of allelic loss in CRC. In an early study, one copy of 18q was lost in 73 percent of sporadic CRCs and 47 percent of large adenomas with foci of invasive cancer, but in fewer than 15 percent of less advanced adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/30\">",
"     30",
"    </a>",
"    ]. In 1989, a candidate gene termed the \"deleted in colon cancer\" (DCC) gene was identified at 18q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/71\">",
"     71",
"    </a>",
"    ], and point mutations in the DCC gene have been identified in CRCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene mutations presumably lead to a loss of expression of the DCC protein, which is thought to have a role in cell&ndash;cell or cell&ndash;matrix interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/71,74,75\">",
"     71,74,75",
"    </a>",
"    ]. DCC is normally expressed in many tissues, including the colonic mucosa, although its normal function has been difficult to elucidate because of its large size and the lack of expression in CRCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of DCC expression may have prognostic value, particularly in patients with early stage CRC. Five-year survival rates seem to be worse for patients with stage II (node-negative, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 3",
"    </a>",
"    )) CRCs that lack DCC expression compared to those that express it [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/76\">",
"     76",
"    </a>",
"    ]. For patients with DCC-negative stage II disease, prognosis more closely approximates that of patients with more advanced stage III (node-positive) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultimate benefit of this information may be the identification of a subgroup of patients with stage II colon cancer who might benefit from adjuvant chemotherapy. While appealing, there are no prospective data that currently support the validity of this strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second tumor suppressor gene at 18q was identified during the course of investigation of allelic losses in pancreatic cancer, termed the DPC4 (deleted in pancreatic cancer) gene, now redesignated SMAD4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=see_link&amp;anchor=H4#H4\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\", section on 'Tumor suppressor genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SMAD4 encodes a protein that may be important to the signaling pathway of the transforming growth factor-beta (TGF-beta) superfamily of signaling polypeptides. TGF-beta suppresses the growth of most normal cells by binding to type I (TGFBR1) and type II (TGFBR2) transmembrane receptors, but many cancer cells are resistant to this growth-suppressive effect. In CRC cells, SMAD4 is required for TGF-beta signaling, and at least in vitro, reintroduction of the gene (via transfection of an intact chromosome 18) is associated with restoration of TGF-beta sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in SMAD4 or a third putative tumor suppressor gene that also maps to 18q (SMAD2) have been found in a subset of sporadic CRCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. Perhaps more importantly, germline mutations in SMAD4 (and in BMPR1A, a gene that codes for a member of the TGF-beta receptor superfamily, which is located upstream from SMAD4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/84\">",
"     84",
"    </a>",
"    ]) have also been identified in patients with juvenile polyposis. These patients develop multiple juvenile polyps that are distinct from adenomas, and they are at an increased risk for invasive CRCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759704#H21759704\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Juvenile polyposis syndrome and familial juvenile polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     TGF-beta signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, one mechanism by which CRC cells escape the normal inhibitory influence of TGF-beta is through SMAD4 mutations, which interfere with the production of a protein that is required for TGF-beta signaling. Other possible mechanisms of interference with normal TGF-beta signaling in CRC cells have also been identified, including inactivating mutations in TGFBR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/85\">",
"     85",
"    </a>",
"    ] and molecular changes that result in the redirection of TGF-beta growth inhibitory signals into growth stimulatory signals.",
"   </p>",
"   <p>",
"    As an example, TGFRB1*6A is a common polymorphism of the type I TGF-beta receptor (TGFBR1) which, in epidemiologic studies, has been linked to an increased risk of cancer, including CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. The mechanism underlying enhanced tumor susceptibility was suggested in a study showing that the interaction of TGF-beta with TGFRB1*6a in tumor cells resulted in a stimulatory rather than an inhibitory signal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/88\">",
"     88",
"    </a>",
"    ]. TGFRB1*6A was somatically acquired in a high frequency of liver metastases from CRC (13 of 44, 30 percent), but only a small proportion of primary CRCs (4 of 157, 2.5 percent). On the other hand, *6A was present in the germline of 26 of 30 patients with primary CRC.",
"   </p>",
"   <p>",
"    The difference in the interaction of TGF-beta with TGFRB1 and TGFRB1*6a was attributed not to differences in the structure of the mature receptor (which was identical), but to a shorter signal sequence in the *6A receptor. Signal sequences play a key role in membrane insertion for secretory and membrane proteins, after which they are cleaved off from the precursor protein. The high frequency of somatic acquisition in liver metastases and the absence of loss of heterozygosity at the TGFRB1 locus suggest that *6A may act as a dominant allele that confers a growth advantage to tumor cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mismatch repair genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mismatch repair (MMR) genes are responsible for correcting the ubiquitous nucleotide base mispairings and small insertions or deletions that occur during DNA replication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. Several of these genes exist, including hMSH2 (human mutS homolog 2), hMLH1 (human mutL homolog 1), hPMS1 and hPMS2 (human postmeiotic segregation 1 and 2), hMSH6 (human mutS homolog 6), and hMLH3, a mismatch-repair gene that interacts with MLH1.",
"   </p>",
"   <p>",
"    Germline mutations in one of the MMR genes appear to be the underlying genetic defect in most kindreds with hereditary nonpolyposis colorectal cancer (HNPCC), and loss of expression of MMR genes can also be found in approximately 15 percent of sporadic colorectal cancers (CRCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. However, sporadic tumors with defective expression of MMR genes do not contain MMR gene mutations; instead, they have epigenetic changes that silence gene expression (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Epigenetic alterations affecting MMR genes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Some patients who meet clinical criteria for Lynch syndrome (eg, the Amsterdam criteria (",
"    <a class=\"graphic graphic_table graphicRef59832 \" href=\"UTD.htm?3/37/3675\">",
"     table 4",
"    </a>",
"    )) do not have a discernible mutation in one of the MMR genes. This subset of patients is termed familial colorectal cancer syndrome X, to distinguish them from Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/3,96-98\">",
"     3,96-98",
"    </a>",
"    ]. However, although this is termed &ldquo;familial&rsquo;, this may be a misnomer, as it may more likely be an inherited syndrome but one in which we do not yet know the causative germline mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Amsterdam criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing strategies for Lynch syndrome in patients with colorectal cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43799536\">",
"    <span class=\"h3\">",
"     MSI-high versus MSI-low",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cells with MMR deficiency accumulate DNA errors throughout the genome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/99\">",
"     99",
"    </a>",
"    ]. The biologic \"footprint\" of an MMR defect is the accumulation of abnormalities in short sequences of nucleotide bases that are repeated dozens to hundreds of times within the genome; these are called microsatellites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/99\">",
"     99",
"    </a>",
"    ]. Several critical growth regulatory genes (eg, the transforming growth factor beta type II receptor, BAX, the insulin like growth factor II receptor) contain microsatellites in the promoter region and are therefore susceptible to frameshift mutations. This leaves the cell vulnerable to mutations in these genes controlling cell growth, and this phenomenon is termed microsatellite instability (MSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/85,99,100\">",
"     85,99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many but not all tumors that contain MMR mutations can be identified by the presence of a high degree of MSI (MSI-high, MSI-H). The majority of patients with HNPCC have MSI-H tumors. In addition, approximately 15 percent of sporadic tumors are MSI-H. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to microsatellite-stable CRCs, sporadic tumors with MSI have characteristic clinicopathologic features. They tend to occur in the proximal colon, have a greater mucinous component, contain lymphocytic infiltration, and are more often poorly differentiated. Interestingly, the tendency to have a lymphocytic infiltrate likely reflects immune activation from T-cells directed against tumor-specific carboxy-terminal frameshift peptides that are associated with microsatellite instability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/101\">",
"     101",
"    </a>",
"    ]. This observation offers the potential to develop vaccination approaches against MSI-H colorectal cancers.",
"   </p>",
"   <p>",
"    Although tumors in HNPCC tend to be poorly differentiated, the presence of MSI has been associated with longer survival in both HNPCC and sporadic cases, for unclear reasons. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Category IIB factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most laboratories use a panel of several microsatellite loci when testing for MSI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/102\">",
"     102",
"    </a>",
"    ]. A panel consisting of three dinucleotide repeats and two mononucleotide repeats has been proposed as a standard test for MSI; a tumor is called MSI-H when at least two (40 percent) are affected by instability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/93\">",
"     93",
"    </a>",
"    ]. While most tumors show either a high degree of instability or no unstable markers, a minority display instability in &lt;40 percent of the markers studied. These tumors are referred to as MSI-low (MSI-L). While almost all MSI-H tumors are MMR deficient, most MSI-L tumors have no MMR defect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of the MSI-L phenotype is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/103,105,106\">",
"     103,105,106",
"    </a>",
"    ]. It is not associated with silencing of MLH1 or any of the other known DNA mismatch repair genes, but there is evidence to suggest that MSI-L is a nonrandom phenomenon with a biologic basis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Some data suggest that MSI-L in sporadic CRC reflects loss of the MutS Homologue 3 (MSH3) gene and is predictive of a poor clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/106\">",
"     106",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The MSI-L phenotype has also been associated with methylation of the promoter for the DNA repair gene O-6 methylguanine DNA methyltransferase (MGMT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/109\">",
"     109",
"    </a>",
"    ]. It has been hypothesized that loss of expression of MGMT results in accumulation of methyl G:T mismatches and excess stress on the mismatch repair system, which ultimately leads to MSI-L [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. While rare in HNPCC, MGMT methylation of loss or MGMT expression occurs in up to 25 percent of sessile serrated adenomas, 78 percent of dysplastic serrated adenomas, and 50 percent of serrated adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. These findings suggest that the factors leading to the MSI-L phenotype may be important in the serrated",
"    <span class=\"nowrap\">",
"     neoplasia/CIMP",
"    </span>",
"    pathway (",
"    <a class=\"graphic graphic_table graphicRef72239 \" href=\"UTD.htm?28/53/29532\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Epigenetic alterations affecting MMR genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, mutations and allelic loss of one of the MMR genes are responsible for the MSI phenotype in most cases of HNPCC. In contrast, hypermethylation of the promoter region of some MMR genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DNA hypomethylation with loss of imprinting (ie, silencing of gene expression) is thought to underlie cases of sporadic CRC that display the MSI phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/89,112-117\">",
"     89,112-117",
"    </a>",
"    ]. Epigenetic inactivation of the second normal MMR gene allele may also play a role in individuals with HNPCC, in whom the second allele must be inactivated in order to progress to cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DNA hypermethylation specifically targets CpG dinucleotides, which are present in the promoters of many genes (including the MMR gene hMLH1). Although the stimulus that drives hypermethylation remains unknown, methylated CpG is bound by a family of proteins known as methyl-CpG binding domain proteins. These proteins, in turn, form a multiprotein complex that alters chromatin conformation and silences gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/120-122\">",
"     120-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another mechanism of epigenetic inactivation is DNA hypomethylation and loss of imprinting (LOI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/10\">",
"     10",
"    </a>",
"    ] . Imprinting refers to the selective loss of expression of parent lineage-specific genes due to selective methylation of one allele. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link&amp;anchor=H1497302#H1497302\">",
"     \"Basic principles of genetic disease\", section on 'Imprinting'",
"    </a>",
"    .) This pattern is set in the zygote and maintained during development to suppress the expression of the maternal or paternal copy of an allele. LOI for the insulin-like growth factor II (IGF-II) gene has been highly associated with MMR-positive CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/116,117,123\">",
"     116,117,123",
"    </a>",
"    ]. However, LOI for IGF-II is found more often in the normal colonic mucosa and peripheral blood lymphocytes of patients with CRC compared to those without the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/116,124\">",
"     116,124",
"    </a>",
"    ]. These findings have led some to hypothesize that LOI for IGF-II represents a risk factor for CRC rather than a somatic defect underlying tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     MUTYH defects and familial CRC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients with multiple colorectal adenomas and a family history of CRC have germline mutations (often biallelic) in the base excision repair gene mutY homolog (MYH, or MUTYH), sometimes in conjunction with somatic mutations in the APC gene [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. These mutations predispose patients to recessive inheritance of multiple colonic adenomas and a variant form of familial adenomatous polyposis (FAP), frequently referred to as MUTYH-associated polyposis (MAP). In one series of 152 patients with multiple adenomas seen at one institution, 7.5 percent of those without a germline APC mutation were found to have two separate germline MUTYH mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/125\">",
"     125",
"    </a>",
"    ]. These findings have implications for screening strategies in patients suspected of having FAP, which in most cases are inherited in an autosomal dominant pattern (see",
"    <a class=\"local\" href=\"#H13\">",
"     'APC gene'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Perhaps more importantly, an increasing number of reports suggest that germline mutations in these MUTYH genes may account for a substantial fraction of familial colorectal cancers that occur in the absence of a dominantly inherited familial syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/127-132\">",
"     127-132",
"    </a>",
"    ]. In a population-based series that screened 1238 patients diagnosed with colorectal cancer over a three-year period and 1255 healthy age- and gender-matched control subjects without a personal history of cancer for germline MUTYH mutations (Y165C and G382D), mutation carriers were significantly more likely to develop CRC and were more likely to have first- or second-degree relatives with CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenotype is variable, ranging from 10 or more polyps to widespread polyposis with associated CRC. The risk of CRC among carriers of biallelic mutations appears to be high; it was close to 100 percent by age 60 in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/133\">",
"     133",
"    </a>",
"    ], and 43 percent in another [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/134\">",
"     134",
"    </a>",
"    ]. Some data suggest that heterozygotes have a slightly increased risk of CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/129,135,136\">",
"     129,135,136",
"    </a>",
"    ], while other series report no increased risk in those with monoallelic mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis may be more favorable in colorectal cancers that develop in the setting of MAP compared to those that arise in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/137\">",
"     137",
"    </a>",
"    ]. In a retrospective European cohort study comparing 147 patients with MAP-related colorectal cancer and 272 population-based matched control patients with colorectal cancer, survival was significantly better for the patients with MAP-associated cancers, even after adjustment for differences in age, stage, sex, subsite, country, and year of diagnosis (hazard ratio (HR) for death 0.48, 95% CI 0.32 to 0.72). Though compelling, these findings should be replicated in independent, prospective studies. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Modifier genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the genes described, several other genes seem to be important in colorectal carcinogenesis, although their exact roles and mechanisms of tumorigenesis have not been fully determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     COX-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial body of evidence supports a protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other cyclooxygenase (COX) inhibitors on the development of CRC. Furthermore, one nonspecific COX inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    , can cause polyp regression in patients with FAP. The mechanism underlying these effects is not well understood, but they suggest a role for COX-2, which is upregulated in CRC cells, in colorectal tumorigenesis. This is an area of active investigation and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     PPAR gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peroxisome proliferator&ndash;activating receptor gene (PPAR) has been implicated in colorectal carcinogenesis. The PPAR gene encodes a family of nuclear receptors that function as transcriptional regulators for proteins controlling lipid metabolism and cell growth. Activation of these receptors inhibits cell growth and promotes differentiation in a variety of epithelial cell types, including CRC cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/138\">",
"     138",
"    </a>",
"    ]. Preliminary studies demonstrate that PPAR gene is downstream from the APC gene and may also be involved in the COX pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/139-142\">",
"     139-142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of function mutations in PPAR has been described in sporadic CRCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/143\">",
"     143",
"    </a>",
"    ]. Furthermore, there is some evidence that abnormalities in the PPAR genes are responsible for the increased frequency of CRCs and adenomas in patients with acromegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H14#H14\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231983740\">",
"    <span class=\"h1\">",
"     FAMILIAL CRC WITHOUT A DISCERNIBLE INHERITED SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the preceding sections, specific germline mutations are responsible for the inherited CRC syndromes, while a stepwise accumulation of somatic mutations is thought to underlie most sporadic cases. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathways to colorectal tumorigenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, the mechanisms underlying familial clustering of CRC in the absence of a discernible inherited syndrome remain incompletely understood.",
"   </p>",
"   <p>",
"    There is a lack of evidence for a strong link between CpG island methylator phenotype (CIMP) and familial CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least in persons of Ashkenazi Jewish descent, a specific mutation in the adenomatous polyposis coli (APC) gene has been linked with a familial but non-syndromic pattern of CRC (see",
"    <a class=\"local\" href=\"#H13\">",
"     'APC gene'",
"    </a>",
"    above). Others have postulated that these families represent a variant of HNPCC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/146\">",
"     146",
"    </a>",
"    ], and in fact, abnormalities of DNA mismatch repair genes have been reported in a substantial proportion of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/128-130\">",
"     128-130",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Mismatch repair genes'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    However. results from genomewide association studies suggest that there may in fact be a large number of independent variants (single nucleotide polymorphisms) at multiple susceptibility loci that have a credible association with CRC, some of which are common, each exerting a small influence on risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer represents an ideal model for the study of molecular pathogenesis of cancer due to the accessibility of tissue for biopsy and the clear progression from normal colonic epithelium to invasive cancer via an intermediate precursor, the adenomatous polyp. A multistep process of specific genetic changes is thought to drive the transformation from normal colonic epithelium to an invasive cancer. Single, specific germline mutations underlie the common inherited syndromes (eg, APC, HNPCC), while sporadic cancers result from the stepwise accumulation of multiple somatic mutations. Mutations in the APC gene occur early, while others, such as mutations of the p53 suppressor gene, generally occur late in the process (",
"    <a class=\"graphic graphic_figure graphicRef55601 \" href=\"UTD.htm?39/62/40941\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Molecular pathogenesis of CRC'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The concept of microsatellite instability (MSI) provides an additional layer of complexity to this model. The MSI-high (MSI-H) phenotype is associated with HNPCC syndrome and also observed in approximately 10 to 15 percent of sporadic colorectal cancers. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'The mutator phenotype/mismatch repair pathway'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The available data suggest that most colorectal neoplasias begin with inactivation (through a germline or sporadic mutation) of the APC gene, whether or not MSI is present. However, the genetic events may thereafter diverge, depending upon the mechanism underlying genetic instability (ie, chromosomal instability, germline mutations in DNA mismatch repair enzymes, CpG Island hyperMethylation Phenotype [CIMP+]). This has led to the molecular classification of colorectal cancer into three carcinogenic pathways (",
"    <a class=\"graphic graphic_table graphicRef72239 \" href=\"UTD.htm?28/53/29532\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/33/30234/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathways to colorectal tumorigenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compared to patients with chromosomal instability (which includes those with familial adenomatous polyposis [FAP] and the majority of sporadic CRCs), the MSI-H or \"mutator\" pathway involves a unique destabilizing mechanism and inactivation of a different set of genes. The CIMP+ pathway involves hypermethylation of the gene promoter for a DNA mismatch repair gene. Regardless of the molecular pathway involved, the final result is the same.",
"   </p>",
"   <p>",
"    In contrast, the genetic abnormalities underlying &ldquo;familial&rdquo; CRC in the absence of a discernible inherited syndrome remain incompletely understood. (See",
"    <a class=\"local\" href=\"#H1231983740\">",
"     'Familial CRC without a discernible inherited syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to providing insight as to the biology of all CRCs, the identification of specific genetic mutations responsible for colorectal tumorigenesis has had a direct influence on clinical care. Patients at highest risk for developing CRC can be identified via genetic testing for specific germline mutations, and new molecular screening methods for early detection of CRC by detection of mutations in fecal material are under study. In addition, these mutations are also being examined as prognostic markers and as potential therapeutic targets.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/2\">",
"      Wirtzfeld DA, Petrelli NJ, Rodriguez-Bigas MA. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann Surg Oncol 2001; 8:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/3\">",
"      Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am 2009; 18:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/4\">",
"      Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/5\">",
"      Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/6\">",
"      Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009; 4:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/7\">",
"      Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/8\">",
"      Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22:4632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/9\">",
"      Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/10\">",
"      van Engeland M, Derks S, Smits KM, et al. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011; 29:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/11\">",
"      Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/12\">",
"      Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/13\">",
"      Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/14\">",
"      Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/15\">",
"      Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/16\">",
"      Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003; 63:4878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/17\">",
"      Lynch JP, Hoops TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am 2002; 16:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/18\">",
"      Sherr CJ. Cancer cell cycles. Science 1996; 274:1672.",
"     </a>",
"    </li>",
"    <li>",
"     Cancer Genetics and Cancer Predisposition Testing. In: American Society of Clinical Oncology Curriculum, American Society of Clinical Oncology (Ed), Alexandria, VA 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/20\">",
"      Forgacs I. Oncogenes and gastrointestinal cancer. Gut 1988; 29:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/21\">",
"      Cartwright C. Intestinal cell growth control: role of Src tyrosine kinases. Gastroenterology 1998; 114:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/22\">",
"      Hamilton SR. The molecular genetics of colorectal neoplasia. Gastroenterology 1993; 105:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/23\">",
"      Kapitanovi S, Radosevi S, Kapitanovi M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/24\">",
"      Irby RB, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/25\">",
"      Takayama T, Ohi M, Hayashi T, et al. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001; 121:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/26\">",
"      Shibata D, Schaeffer J, Li ZH, et al. Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. J Natl Cancer Inst 1993; 85:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/27\">",
"      Tortola S, Marcuello E, Gonz&aacute;lez I, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/28\">",
"      Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/29\">",
"      Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/30\">",
"      Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/31\">",
"      Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004; 10:4015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/32\">",
"      Harada K, Hiraoka S, Kato J, et al. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 2007; 97:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/33\">",
"      Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005; 386:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/34\">",
"      Miranda E, Destro A, Malesci A, et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 2006; 95:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/35\">",
"      Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 1993; 85:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/36\">",
"      Losi L, Roncucci L, di Gregorio C, et al. K-ras and p53 mutations in human colorectal aberrant crypt foci. J Pathol 1996; 178:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/37\">",
"      Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/38\">",
"      Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/39\">",
"      Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/40\">",
"      Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/41\">",
"      Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/42\">",
"      Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989; 244:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/43\">",
"      Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/44\">",
"      Drucker L, Shpilberg O, Neumann A, et al. Adenomatous polyposis coli I1307K mutation in Jewish patients with different ethnicity: prevalence and phenotype. Cancer 2000; 88:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/45\">",
"      Spirio LN, Samowitz W, Robertson J, et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 1998; 20:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/46\">",
"      Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999; 5:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/47\">",
"      Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993; 262:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/48\">",
"      Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/49\">",
"      Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/50\">",
"      Uthoff SM, Eichenberger MR, McAuliffe TL, et al. Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Mol Carcinog 2001; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/51\">",
"      Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/52\">",
"      Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/53\">",
"      Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/54\">",
"      van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/55\">",
"      Shih IM, Wang TL, Traverso G, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci U S A 2001; 98:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/56\">",
"      Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/57\">",
"      Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/58\">",
"      Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000; 910:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/59\">",
"      Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/60\">",
"      Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992; 52:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/61\">",
"      Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23:7518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/62\">",
"      Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/63\">",
"      Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/64\">",
"      Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992; 89:7491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/65\">",
"      Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001; 264:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/66\">",
"      Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/67\">",
"      Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/68\">",
"      Warren RS, Kirn DH. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg Oncol Clin N Am 2002; 11:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/69\">",
"      Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/70\">",
"      Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A 2000; 97:8490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/71\">",
"      Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/72\">",
"      Hedrick L, Cho KR, Fearon ER, et al. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994; 8:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/73\">",
"      Chan SS, Zheng H, Su MW, et al. UNC-40, a C. elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues. Cell 1996; 87:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/74\">",
"      Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/75\">",
"      Cho KR, Oliner JD, Simons JW, et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 1994; 19:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/76\">",
"      Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/77\">",
"      Sun XF, R&uuml;tten S, Zhang H, Nordenskj&ouml;ld B. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 1999; 17:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/78\">",
"      Goyette MC, Cho K, Fasching CL, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992; 12:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/79\">",
"      Reiss M, Santoro V, de Jonge RR, Vellucci VF. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: evidence for tumor suppression by Smad4/DPC4. Cell Growth Differ 1997; 8:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/80\">",
"      Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. Nat Genet 1996; 13:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/81\">",
"      Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/82\">",
"      MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997; 15:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/83\">",
"      Xie W, Rimm DL, Lin Y, et al. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 2003; 9:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/84\">",
"      Zhou XP, Woodford-Richens K, Lehtonen R, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 2001; 69:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/85\">",
"      Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/86\">",
"      Bian Y, Caldes T, Wijnen J, et al. TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol 2005; 23:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/87\">",
"      Pasche B, Kaklamani V, Hou N, et al. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 2004; 22:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/88\">",
"      Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005; 294:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/89\">",
"      Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology 1995; 109:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/90\">",
"      Papadopoulos N, Nicolaides NC, Liu B, et al. Mutations of GTBP in genetically unstable cells. Science 1995; 268:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/91\">",
"      Baker SM, Bronner CE, Zhang L, et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 1995; 82:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/92\">",
"      Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/93\">",
"      Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/94\">",
"      Syngal S, Weeks JC, Schrag D, et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/95\">",
"      Shibata D, Peinado MA, Ionov Y, et al. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/96\">",
"      Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012; 25:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/97\">",
"      Klarskov L, Holck S, Bernstein I, Nilbert M. Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. J Clin Pathol 2012; 65:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/98\">",
"      Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/99\">",
"      Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/100\">",
"      Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998; 153:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/101\">",
"      Schwitalle Y, Kloor M, Eiermann S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/102\">",
"      Hatch SB, Lightfoot HM Jr, Garwacki CP, et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res 2005; 11:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/103\">",
"      de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010; 28:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/104\">",
"      Mueller J, Gazzoli I, Bandipalliam P, et al. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res 2009; 69:7053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/105\">",
"      Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998; 58:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/106\">",
"      Haugen AC, Goel A, Yamada K, et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 2008; 68:8465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/107\">",
"      Halford S, Sasieni P, Rowan A, et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002; 62:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/108\">",
"      Halford SE, Sawyer EJ, Lambros MB, et al. MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol 2003; 201:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/109\">",
"      Whitehall VL, Walsh MD, Young J, et al. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001; 61:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/110\">",
"      Dong SM, Lee EJ, Jeon ES, et al. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005; 18:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/111\">",
"      Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology 2006; 49:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/112\">",
"      Weinberg RA. Oncogenes and tumor suppressor genes. CA Cancer J Clin 1994; 44:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/113\">",
"      Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998; 95:8698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/114\">",
"      Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95:6870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/115\">",
"      Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/116\">",
"      Cui H, Horon IL, Ohlsson R, et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998; 4:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/117\">",
"      Nakagawa H, Chadwick RB, Peltomaki P, et al. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 2001; 98:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/118\">",
"      Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/119\">",
"      Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/120\">",
"      Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/121\">",
"      Tycko B. Epigenetic gene silencing in cancer. J Clin Invest 2000; 105:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/122\">",
"      Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/123\">",
"      Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/124\">",
"      Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/125\">",
"      Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/126\">",
"      Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003; 362:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/127\">",
"      Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004; 127:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/128\">",
"      Ricciardiello L, Goel A, Mantovani V, et al. Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res 2003; 63:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/129\">",
"      Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 2004; 96:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/130\">",
"      Enholm S, Hienonen T, Suomalainen A, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol 2003; 163:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/131\">",
"      Kambara T, Whitehall VL, Spring KJ, et al. Role of inherited defects of MYH in the development of sporadic colorectal cancer. Genes Chromosomes Cancer 2004; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/132\">",
"      Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C--&gt;T:A mutations in colorectal tumors. Nat Genet 2002; 30:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/133\">",
"      Farrington SM, Tenesa A, Barnetson R, et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005; 77:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/134\">",
"      Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009; 27:3975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/135\">",
"      Webb EL, Rudd MF, Houlston RS. Colorectal cancer risk in monoallelic carriers of MYH variants. Am J Hum Genet 2006; 79:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/136\">",
"      Croitoru ME, Cleary SP, Berk T, et al. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. J Surg Oncol 2007; 95:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/137\">",
"      Nielsen M, van Steenbergen LN, Jones N, et al. Survival of MUTYH-associated polyposis patients with colorectal cancer and matched control colorectal cancer patients. J Natl Cancer Inst 2010; 102:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/138\">",
"      Gupta RA, Brockman JA, Sarraf P, et al. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001; 276:29681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/139\">",
"      He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/140\">",
"      Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001; 22:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/141\">",
"      Dobbie Z, Muller PY, Heinimann K, et al. Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. Anticancer Res 2002; 22:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/142\">",
"      Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000; 97:13275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/143\">",
"      Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/144\">",
"      Frazier ML, Xi L, Zong J, et al. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res 2003; 63:4805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/145\">",
"      Ward RL, Williams R, Law M, Hawkins NJ. The CpG island methylator phenotype is not associated with a personal or family history of cancer. Cancer Res 2004; 64:7618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/146\">",
"      Pinsky PF. Does hereditary nonpolyposis colorectal cancer explain the observed excess risk of colorectal cancer associated with family history? Epidemiology 2000; 11:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/33/30234/abstract/147\">",
"      Theodoratou E, Montazeri Z, Hawken S, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012; 104:1433.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2485 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-FFAD13B8AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30234=[""].join("\n");
var outline_f29_33_30234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR PATHOGENESIS OF CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The adenoma-carcinoma sequence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Serrated polyp pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular pathways to colorectal tumorigenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - The chromosomal instability (APC) pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - The mutator phenotype/mismatch repair pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypermethylation phenotype (CIMP+) pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC MOLECULAR ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oncogenes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ras",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - APC gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - p53 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chromosome 18q: the DCC, SMAD4, and SMAD2 genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - TGF-beta signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mismatch repair genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43799536\">",
"      - MSI-high versus MSI-low",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Epigenetic alterations affecting MMR genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MUTYH defects and familial CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Modifier genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - COX-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - PPAR gene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231983740\">",
"      FAMILIAL CRC WITHOUT A DISCERNIBLE INHERITED SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2485|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/13/23775\" title=\"figure 1\">",
"      Pathogenesis of CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/62/40941\" title=\"figure 2\">",
"      Genetic model CRC tumorigenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/30/28131\" title=\"figure 3\">",
"      Retinoblastoma formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/17/32019\" title=\"figure 4\">",
"      APC and wnt signaling pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/53/29532\" title=\"table 1\">",
"      Molecular classification of colorectal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/55/43899\" title=\"table 2\">",
"      Gene mutations causing CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 3\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/37/3675\" title=\"table 4\">",
"      Revised Amsterdam criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=related_link\">",
"      Molecular pathogenesis of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_33_30235="Clinical features of central versus peripheral vertigo";
var content_f29_33_30235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of central versus peripheral vertigo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peripheral",
"       </td>",
"       <td class=\"subtitle1\">",
"        Central",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Direction",
"       </td>",
"       <td class=\"sublist_other\">",
"        Unidirectional, fast&nbsp;component toward the normal ear; never reverses direction",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sometimes reverses direction when patient looks in the direction of slow component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type",
"       </td>",
"       <td class=\"sublist_other\">",
"        Horizontal with a torsional component, never purely torsional or vertical",
"       </td>",
"       <td class=\"sublist_other\">",
"        Can be any direction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Effect of visual fixation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Suppressed",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not suppressed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other neurologic signs",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Often present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postural instability",
"       </td>",
"       <td>",
"        Unidirectional instability, walking preserved",
"       </td>",
"       <td>",
"        Severe instability, patient often falls when walking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deafness or tinnitus",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30235=[""].join("\n");
var outline_f29_33_30235=null;
var title_f29_33_30236="HPV types disease associations";
var content_f29_33_30236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease associations with selected human papillomavirus types",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        HPV type frequently associated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Cutaneous warts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plantar wart",
"       </td>",
"       <td class=\"sublist_other\">",
"        1, 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Common wart",
"       </td>",
"       <td class=\"sublist_other\">",
"        2, 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Flat wart",
"       </td>",
"       <td class=\"sublist_other\">",
"        3, 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Butcher's wart",
"       </td>",
"       <td class=\"sublist_other\">",
"        7, 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Bowen's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Genital",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Extragenital",
"       </td>",
"       <td class=\"sublist_other\">",
"        2, 3, 4, 16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermodysplasia verruciformis",
"       </td>",
"       <td>",
"        2, 3, 5, 8, 9, 10, 12, 14, 15, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condylomata acuminata",
"       </td>",
"       <td>",
"        6, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Squamous intraepithelial lesions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low grade",
"       </td>",
"       <td class=\"sublist_other\">",
"        16, 31, 6, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        High grade",
"       </td>",
"       <td class=\"sublist_other\">",
"        16, 31, 52, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oropharyngeal cancer",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal cancer&nbsp;",
"       </td>",
"       <td>",
"        16&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory papillomatosis",
"       </td>",
"       <td>",
"        6, 11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists the more commonly reported human papillomavirus types associated with various&nbsp;conditions. However, the most prevalent HPV types associated with particular lesions&nbsp;can vary by geography and demographics of the population studied.",
"    <div class=\"footnotes\">",
"     * These include squamous intraepithelial lesions and cancers of the cervix, vagina, vulva, anus, and penis.",
"    </div>",
"    <div class=\"reference\">",
"     1.",
"     <em>",
"      Hariri S, Unger ER, Powell SE, et al. Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States. J Infec Dis 2012; 206:1878.",
"      <br>",
"       2. Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611.",
"      </br>",
"     </em>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30236=[""].join("\n");
var outline_f29_33_30236=null;
var title_f29_33_30237="MAP kinase signal cascade";
var content_f29_33_30237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MAP kinase signaling cascade in papillary thyroid carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 130px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the MAP kinase signaling cascade in papillary thyroid carcinoma. Mitogen activated protein kinase (MAPK), also known as intracellular signal-regulated kinase (ERK), translocates to the nucleus and promotes cell division when it is phosphorylated by MEK, a serine/threonine kinase. Constitutive activation of this process is tumorigenic. MAPK phosphorylation is a relatively distal step in a sequential phosphorylation cascade that can begin with the activation of a tyrosine kinase, is followed by phosphorylation of RAS which activates BRAF, a serine/threonine kinase followed by MEK and MAPK phosphorylation. In papillary thyroid carcinoma, somatic genetic alterations at three of these steps activate this linear signaling cascade. A gene rearrangement creating a chimeric RET or TRK activates the initial tyrosine kinase step. Activating point mutations of either RAS or BRAF constitutively activates these proteins. The tyrosine kinase, RAS, and BRAF genetic alterations are usually mutually exclusive, suggesting that any single alteration is sufficient to play an early role in tumorigenesis",
"    <sup>",
"     [1,2]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Melillo RM, Castillone D, Guarino V, et al. The ret/ptc-ras-braf linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068.",
"     <br>",
"      2. Ciampi R, Nikiforov YE. Ret/ptc rearrangements and braf mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30237=[""].join("\n");
var outline_f29_33_30237=null;
var title_f29_33_30238="Risk of mortality among dial pts according to baseline albumin";
var content_f29_33_30238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60944%7ENEPH%2F70749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60944%7ENEPH%2F70749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of mortality among dialysis patients according to baseline albumin at initiation of dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation of the risk of mortality according to the plasma albumin concentration obtained within six weeks of starting maintenance dialysis in 2897 patients receiving hemodialysis and 666 patients treated with continuous ambulatory peritoneal dialysis. Hypoalbuminemia was associated with increased mortality, particularly at plasma concentrations below 3.0 g/dL (30 g/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Held, PJ, Port, FK",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of mortality among hemodialysis patients according to serum albumin during maintenance dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Odds ratio for death, adjusted for age, sex, race, and underlying disease, according to the plasma albumin concentration in patients on maintenance hemodialysis. The likelihood of dying was inversely related to the plasma albumin concentration, being greatest at a plasma albumin concentration below 3.0 g/dL (30 g/L). All values are signficantly different (p&lt;0.001 to 0.03) from the odds ratio of 1.0 at a normal plasma albumin concentration of 4.0 to 4.4 g/dL (40 to 44 g/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Owen, WF Jr, Lew, NL, Liu, Y, et al, N Engl J Med 1993; 329:1001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30238=[""].join("\n");
var outline_f29_33_30238=null;
var title_f29_33_30239="Cross-sectional anatomy of the adrenal gland";
var content_f29_33_30239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross-sectional anatomy of the adrenal gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adrenal glands showing cortex and medulla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_33_30239=[""].join("\n");
var outline_f29_33_30239=null;
